

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

Acupuncture combined with cognitive-behavioral therapy for insomnia (CBT-I) in patients with insomnia: study protocol for a randomized controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-063442
Article Type:	Protocol
Date Submitted by the Author:	12-Apr-2022
Complete List of Authors:	Pei, Wenya; Sun Yat-sen University First Affiliated Hospital He, Te; South China University of Technology Yang, Pei; South China University of Technology Lv, Xiaozhou; Sun Yat-sen University First Affiliated Hospital Jiao, Boyu; Sun Yat-sen University First Affiliated Hospital Meng, Fanqi; Sun Yat-sen University First Affiliated Hospital Yan, Yingshuo; Sun Yat-sen University First Affiliated Hospital Cui, Liqian; Sun Yat-sen University First Affiliated Hospital He, Guanheng; Sun Yat-sen University First Affiliated Hospital Zhou, Xin; Sun Yat-sen University First Affiliated Hospital Wen, Guihua; South China University First Affiliated Hospital Wen, Jingwen; Sun Yat-sen University First Affiliated Hospital Lu, Liming; Guangzhou University of Chinese Medicine
Keywords:	CLINICAL PHYSIOLOGY, Rehabilitation medicine < INTERNAL MEDICINE, COMPLEMENTARY MEDICINE
	•

SCHOLARONE[™] Manuscripts

Acupuncture combined with cognitive-behavioral therapy for insomnia (CBT-I) in patients with insomnia: study protocol for a randomized controlled trial

Wenya Pei¹, Te He², Pei Yang², Xiaozhou Lv³, Boyu Jiao¹, Fanqi Meng¹, Yingshuo Yan⁴, Liqian Cui⁵, Guanheng He¹, Xin Zhou¹, Guihua Wen², Jingwen Ruan¹, Liming Lu⁶

¹Department of Acupuncture, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

² School of Computer Science and Engineering, South China University of Technology, Guangzhou, China

³Department of Traditional Chinese Medicine, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China

⁴Department of Respiratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

⁵Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China ⁶South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China.

Corresponding author:

Liming Lu. South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China. Email: lulimingleon@126.com

Jingwen Ruan. Department of Acupuncture, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Email: ruanjw@163.com

Guihua Wen. School of Computer Science and Engineering, South China University of

Technology, Guangzhou, China. Email: crghwen@scut.edu.cn

Abstract

Introduction

Insomnia affects physical and mental health due to the lack of continuous and complete sleep architecture. Polysomnograms (PSGs) are used to record electrical information to perform sleep architecture using deep learning. Acupuncture combined with cognitive-behavioral therapy for insomnia (CBT-I) could not only improve sleep quality, solve anxiety, depression but also ameliorate poor sleep habits and detrimental cognition. However, the clinical mechanism of this process remain unclear.

Methods and analysis

This randomized controlled trial will evaluate the efficacy and effectiveness of electroacupuncture combined with CBT-I in patients with insomnia. Participants will be randomized to receive either electroacupuncture combined with CBT-I or sham acupuncture combined with CBT-I and followed up for four weeks. The primary outcome is sleep quality, which is evaluated by the Pittsburgh sleep quality index(PSQI). The secondary outcome measures include a measurement of depression severity, anxiety, maladaptive cognitions associated with sleep, and adverse events. Sleep architecture will be assessed using deep learning on PSGs.

Ethics and dissemination

This trial has been approved by the institutional review boards and ethics committees of the First Affiliated Hospital of Sun Yat-sun University (2021763). The results will be disseminated through peer-reviewed journals.

Trial registration number

CTR2100052502

Keywords: insomnia, cognitive behavioral therapy for insomnia, electroacupuncture, randomized controlled trial

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

BMJ Open

Strengths and limitations of this study

- This study will investigate the efficacy and effectiveness of electroacupuncture combined with CBT-I.
- We will observe the effects of electroacupuncture combined with CBT-I on sleep quality and sleep beliefs and attitudes of patients with insomnia.
- We will use deep learning to observe the effects of electroacupuncture combined with CBT-I on sleep architecture in different dimensions.

or oper to the work

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Introduction

Insomnia is characterized by difficulties in initiating or maintaining sleep or impaired daytime functioning, which impact both physical and mental health^[1-3]. The lack of continuous and complete sleep architecture due to long-term fragmented and light sleep in patients with insomnia causes a decrease in sleep quality, which affects daily functions, and even induces anxiety, depression, and other mental symptoms^[4-6]. With the increasing pressures in daily life and work, insomnia is becoming a public health problem that needs to be solved urgently as it worsens the quality of life of patients, burdens caregivers, and increases social and economic costs^[7-9].

Cognitive-behavioral therapy for insomnia (CBT-I) is recommended as first-line treatment for insomnia and may improve sleep quality and alleviate poor sleep cognition in patients with insomnia^[10-12]. During the early stage of treatment, the sleep quality of patients with severe anxiety were improved slowly and the compliance of these patients were poor. Thus, as confirmed in previous studies, acupuncture combined with CBT-I could not only solve anxiety, depression, and other emotions caused by insomnia but also ameliorate poor sleep habits and detrimental cognition^[13-16].

However, there is a lack of rigorous clinical evidence on the treatment of insomnia with acupuncture combined with CBT-I; moreover, the clinical mechanism is unclear. In previous studies, we found that by analyzing polysomnograms (PSGs), electroacupuncture improves sleep architecture and prolongs the duration of slow-wave and rapid-eye-movement (REM) sleep^[17,18]. But whether acupuncture combined with CBT-I improves sleep architecture requires futher research.

During the past decade, the application of deep learning to automatic sleep staging using PSGs has shown promise for understanding the macrostructure of sleep. Deep learning allows the automatic extraction of features from data related to classification tasks, and the performance of deep neural networks continues to improve as the size of the dataset increases^[19-21].

Page 5 of 28

BMJ Open

Using a high-performance automatic sleep staging algorithm to analyze PSGs recordings via deep learning, this study will focus on the effects of electroacupuncture combined with CBT-I on sleep architecture, sleep quality, and sleep attitudes and beliefs in patients with insomnia. Furthermore, this research will provide guidance for electroacupuncture combined with CBT-I using artificial intelligence.

Methods

Study design

The study will be an assessor-blinded, randomized controlled trial. The protocol was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sun University (2021763). We will follow the Consolidated Standards of Reporting Trials and Standards for Reporting Interventions in Clinical Trials of Acupuncture guidelines for the design and reporting of the trial^[22, 23]. The flowchart of the trial is presented in Figure 1, and the schedule of enrolment, interventions, and outcome assessments are presented in Table 1.

Sample size calculations: Referring to the previous litetature^[24], we assume that the expected PSQI value of the observation group is 9.45 ± 1.84 and the control 6.43 ± 2.10 . We determine that a sample size of 11 per group would provide a power of 90% and an alpha level of 0.05, which would allow us to detect a difference in PSQI score between the two groups. Allowing for a 20% dropout rate, a sample size of 30 in each group is sufficient to meet statistical requirements.

Randomization, allocation, and blinding

Patients who are interested in participating in the trial will initially be screened by phone and then asked to participate in a face-to-face interview to conduct further surveys. After recruiting all participants, random numbers will be generated and assigned by a central randomization system of the Clinical Research and Data Center of Guangzhou University of Chinese Medicine. The researcher who will screen the eligible patients after baseline

BMJ	Open
-----	------

		BN	ЛJ Open		36/bmjopen-2022-063442	Pa
		Table 1 Re	search flow cha	rt	33442 o	
	Screening		Observation pha	se	Follow-upgphase	
Project	assession 0 pre-treament	Assession 1 pre-treament	Assession 2 Week 2±1day	Assession 3 Week 4±2day	Assession 4 Week 8+22 day	Unplanned follow-up
Medical history collection	√	-	-	-	er 2022.	
Sign the informed consent form	\checkmark	-	-	-	- D	
Inclusion criteria	V	-	-	-	ownld	
Exclusion criteria	\checkmark	0 -	-	-	Downloaded from http://bmjopen.bmj.com/ on Apri $\sim \times$ - $\sim \sim$ -	
Basic Information	\checkmark		-	-	d fron	
Vital signs	\checkmark	V	\checkmark		√ http://www.analysis.com	*
Index of laboratory inspection	*	*	×	*	*.//bm	
PSG	-	\checkmark			- jjopei	
Pittsburgh sleep quality index(PSQI)	-	\checkmark	V		√ bmj	
Beck depression inventory(BDI)	-	\checkmark	V	V	√ com	
Beck anxiety inventory(BAI)		\checkmark		N	√ on	
DBAS-16	-	\checkmark		\checkmark	-√ ¹ pril	
Adverse Events	-	*	*	*	×	*
Adverse Events Medication records Terminate test evaluation	-	\checkmark	\checkmark		√ b	
Terminate test evaluation	-	*	*	*	ية ما	

Notes: **"X**"Record when necessary; PSG: Long-term scalp electroencephalogram recording; DBAS-16: Dysfunctional Bellefs and Attitudes about Sleep Scale 16 versio

will assign patients to either the treatment or control group. Researchers, which include statisticians, outcome assessors, and data analysts, will all be blinded to patients' group assignments. Although acupuncturists will be not blinded to group assignment, they will not be involved in outcome assessments or data analyses. In addition, all researchers will undergo training for specific procedures before the trial begins.

Participants and recruitment

Patients will be recruited using hospital-based advertisements in the Department of Acupuncture and Department of Neurology of the First Affiliated Hospital of Sun Yat-sen University from January 2022 to December 2025.

The inclusion criteria will be as follows: (1) meets diagnostic criteria for insomnia based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition^[25] and the International Classification of Sleep Disorders, Third Edition^[26], (2) aged 18–65 years, (3) experienced insomnia for more than 1 month but less than 2 years before the start of the trial, (4) voluntarily agrees to participate in the investigation and provides written informed consent before the clinical trial starts.

The exclusion criteria will be as follows: (1) serious cardiovascular, liver, kidney, or hematopoietic system disease, (2) insomnia was caused by a nervous system disease (e.g., stroke or Parkinson's disease), (3) insomnia was caused by a mental disorder, such as depression or anxiety, (4) history of sleep apnea, (5) pregnant or lactating women, (6) have received or currently receiving CBT-I.

Withdrawal criteria will be as follows: (1) patient withdrawal from the trial because of personal reasons, (2) patient has an adverse reaction related to acupuncture and refuses to continue treatment, (3) during the follow-up period, the patient cannot be contacted because of change of address and telephone number.

Intervention

The intervention will begin the day following randomization. All participants will receive 20 treatments (five times per week for 4 weeks).

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Observation group

Acupuncture treatment

Patients' skin will be disinfected with 75% alcohol, and patients will be asked to lie supine and wear eye masks for a better curative effect. Each participant will receive acupuncture treatment from the same acupuncturist who has more than 5 years of clinical experience in acupuncture therapy. The temperature of the treatment room will not be lower than 25°C. Each treatment will last for 30 min.

Patients in the acupuncture group will receive electroacupuncture treatment on Sishenchong (EX-HN1), bilateral Neiguan (PC6), bilateral Taixi (KI3), bilateral Shenmen (HT7), and bilateral Sanyinjiao (SP6). Tube-guided acupuncture needles will be inserted to a depth of 17-25 mm at each acupoint (acupuncture location and method for each acupoint are provided in Table 2). A low-frequency electronic pulse therapy instrument (G6805-2A, Shanghai Huayi Medical Instrument Co., Shanghai, China) will be used between the two sets of acupoints.

CBT-I treatment

CBT-I will be given while acupuncture treatment is in progress. The intervention will consist of behavioral components (e.g. sleep restriction and stimulus control), cognitive components (e.g., cognitive restructuring and paradoxical intention), progressive muscle relaxation, and sleep hygiene^[27].

Control group

The procedure for the control group will be the same as that for the observation group, with the major difference in interventions between the two groups being the tube needling method, in which no needle will be inserted through the tube for patients in the control group. To mimic the sensation of a real needle being inserted into the body, the acupuncturist will place the tube close to the skin at the acupoint and tap the top of the tube.

Quality control

	BMJ Open	36/bmj
		pen-2022
		2-06344
	Table 2Acupuncture location and method for each	n acupoint 36/bmjopen-2022-063442 Dec Needling method
Acupoint	Location	Needling method
Sishenchong (EX-HN1)	On the parietal region, 1 cun anterior ,posterior and lateral to Baihui, 4 acpoints totally.	The angle between the needle tip are the scalp is 30 Move the needle the backward along the anterioreposterior midline, and then moves the needle 0 cun.
Neiguan(PC6)	On the line joining Daling and Quze, between the tendons of palmaris longus and flexor carpi radialis, 2 cun above the transverse crease of the wrist.	Puncture perpendi gularly 1-1.5 cun.
Taixi (KI3)	In the depression between the tip of the medial malleolus and the Achilles tendon.	Puncture perpendicularly 0.5-1 cun.
Shenmen (HT7)	On the palmar ulnar end of the transverse crease of the wrist, and on the radial aspect of the tendon of the ulnar flexor m. of the wrist.	Puncture perpendicularly 0.5-1 cun.
Sanyinjiao (SP6)	Posterior to the mesial border of the tibia, and 3 cun above the tip of the medial malleolus	- <u>-</u> -
		18, 2024 b
		y guest.
		Protecter
		by guest. Protected by copyright
	For peer review only - http://bmjopen.bmj.com/site/about/gui	delines.xhtml

The trial will be conducted under the supervision of the First Affiliated Hospital of Sun Yat-sun University. A qualified clinical trial expert will be invited to monitor the study to identify problems during the trial, examine collected data, and control bias.

Outcome measures

Primary outcome

Pittsburgh sleep quality index

The Pittsburgh sleep quality index (PSQI) is an internationally established tool that is used to evaluate sleep quality. The scale includes seven dimensions that consist of subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, sleeping medication, and daytime dysfunction. The score correlates adversely with sleep quality which a higher score means the sleep quality is worse, and each factor has a score of 0 to 3 to provide a total score of 21 points^[28, 29].

Secondary outcomes

The Beck depression inventory

The Beck depression inventory (BDI) is a valid self-assessment index to measure depression severity and consists of 13 items. Each item is scored from 0 to 3 (0 to 4 indicates no depression, 5 to 7 indicates mild depression, 8 to 15 indicates moderate depression), with a score of 16 points or more considered as severe depression^{[30-32].}

The Beck anxiety inventory

The Beck anxiety inventory (BAI) is used to assess the degree of anxiety and consists of 21 items scored from 1 to 4 (15 to 25 points indicates mild anxiety, 26 to 35 points indicates moderate anxiety, and 36 points is considered severe anxiety)^[33, 34].

The Dysfunctional Beliefs and Attitudes about Sleep Scale 16 version

The Dysfunctional Beliefs and Attitudes about Sleep Scale 16 version (DBAS-16) is used to evaluate maladaptive cognitions associated with sleep. There are 16 items in the index, which are divided into four factors comprising consequences of insomnia, worry about sleep, sleep expectations, and medication. These factors are scored on a scale of 1-5

BMJ Open

(strongly disagree to strongly agree). The total score is positively correlated with the reasonableness of sleep beliefs and attitudes^[35, 36].

Sleep staging

The PARADISEP&D9600 (U.S.) Polysomnography Monitoring and Analysis System will be used to simultaneously monitor EEG, EOG, and EMG. A large clinical dataset of PSG recordings will be used to train a hybrid convolutional neural network (CNN) and recurrent neural network (RNN) to learn effective and generalizable features for sleep stage scoring^[37, 38]. Then clinical data will be used to indentify the deep learning algorithm. Sleep staging for both datasets will be performed by expert sleep technicians in nonoverlapping 30-s epochs according to standards by the American Academy of Sleep Medicine(AASM), as one of five stages: wake(W), non-rapid eye movement(REM) stage 1(N1), non-REM stage 2(N2), non-REM stage 3(N3), and rapid eye movement (REM)^[39].

Adverse events

During treatment and four week after treatment, a questionnaire will be administered to evaluate the various discomforts that may be caused by acupuncture: hangover, addiction, tolerance, fatigue after waking, insomnia rebound, daytime alertness, cognitive function, and behavior ability.

Patients and public involvement

Patients and the public are not involved in the design or conduct of the study or the outcome measures, and no attempt will be made to assess the burden of the intervention on the patients themselves. The results of this study will be disseminated to study participants via the website of our hospitals.

Statistical analysis

All analyses will be performed on the intention-to-treat population of participants who had at least one treatment. Missing data will be replaced according to the principle of the last observation carried forward. Data analyses will be performed using the SPSS version

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

25 (IBM Corp.) software. All available data will be analyzed descriptively. For continuous data, the normality test will be applied at the beginning of the analysis. Results will be presented as means, standard deviations, and 95% confidence intervals (CIs) for continuous data that conform to the normal distribution and medians, quartiles, and ranges for rank data and continuous data that are not normally distributed. Discrete data will be presented as percentages.

We will first examine the descriptive data for sample characteristics at baseline, and independent samples t-tests will be used to compare groups for continuous variables, whereas chi-square analysis will be used to compare groups for dichotomous variables. Second, we will perform two series of repeated-measures and univariate analyses of covariance (ANCOVA) models to examine treatment effects. We will use repeated-measures ANCOVAs to analyze the primary and secondary outcome measures (i.e., PSQI, BDI, BAI, DBAS-16, and sleep staging scores) from pre-treatment to post-treatment. If a significant effect is observed, we will conduct posthoc paired samples t-tests to examine within-group changes in study outcomes. For all study outcomes, we will then perform univariate ANCOVAs to test for group differences in post-treatment values while controlling for relevant covariates. This process will be repeated to examine changes in study outcomes from pre-treatment to postnatal follow-up.

When necessary, sensitivity analysis will be used to assess the robustness of the conclusions of the entire clinical trial. To evaluate the consistency of the trial and explore the factors that affect efficacy or prognosis, subgroup analysis will be conducted to identify the population with better efficacy. Safety analysis will be used to assess the incidence of adverse events and related symptoms in patients with insomnia during treatment and follow-up.

Discussion

Currently, the main treatments recommended for insomnia are non-pharmaceutical and pharmaceutical treatments. Pharmaceutical treatments include benzodiazepines as well as new non-benzodiazepine drugs, which can shorten the latency to fall asleep and prolong total sleep time but also affect normal sleep physiology and cause adverse reactions ^[40, 41]. CBT-I, which is recommended as a first-line treatment for insomnia by the European insomnia guidelines, is limited in clinical practice because of insufficient professional therapists and poor compliance of patients with insomnia, especially in developing countries such as China^[42-44].

As a complementary alternative therapy with a long history in China, acupuncture has been used as a clinical treatment for insomnia with fewer adverse effects and less permanent damage. Previous studies showed that either acupuncture or CBT-I could produce clinically meaningful improvements in insomnia symptoms, and our preliminary research have confirmed that acupuncture combined with CBT-I also alleviate not only insomnia symptoms but also negative emotions such as anxiety and depression^[13, 14, 16]. But whether acupuncture combined with CBT-I could influence sleep habits and correct cognition, and what the clinic clinical mechanism worth futher research.

To ameliorate sleep habits, correct cognition, and alleviate anxiety, depression, and other emotions caused by insomnia, this study will use electroacupuncture combined with CBT-I and observe sleep architecture, sleep quality, and sleep attitudes and beliefs in patients with insomnia. In this study, PSQI will be used to assess the sleep quality, BDI and BAI will be used to evaluate the depression severity and anxiety. At the same time, we will use DBAS-16 to evaluate the sleep beliefs and attitudes before and after treatment. Because of the particularity of acupuncture therapy, the implementation of blinding is difficult in clinical research^[45, 46]. A research team composed of researchers, therapists, testers, and statisticians will be established to reduce any bias that may occur

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

during the research process by blinding testers and statisticians. This study will provide clinical evidence for the effect and safety of electroacupuncture combined with CBT-I and provide a decision-making reference for clinicians, patients, and policymakers.

To analyze the effects of electroacupuncture combined with CBT-I on sleep architecture and sleep quality in patients with insomnia, deep learning will be used to analyze PSGs in various clinical settings in this study. PSGs are used widely for clinical evaluation because they are more sensitive than routine EEGs (typically 30–60 min duration) in capturing paroxysmal electrical abnormalities^[47, 48]. During the past decade, there have been various advances in automated sleep staging of PSGs data using the ability of deep learning methods to automatically extract features from data that are relevant to the classification; moreover, the performance of deep neural networks continues to improve as datasets become larger^[49-52]. Using deep learning, this study will develope a high-performing, reference channel-free, automated sleep staging algorithm to analyze the sleep architeture which will provide a clinical mechanism in artificial intelligence.

In summary, this study will use electroacupuncture combined with CBT-I to treat insomnia and observe the sleep beliefs and attitudes of patients with insomnia in different dimensions using deep learning. Moreover, we will provide a solid research basis for the combined application of electroacupuncture and CBT-I for insomnia in the clinic.

Acknowledgments Not applicable.

Footnotes

Contributors: Wenya Pei and Te He designed the trial protocol and drafted the manuscript. Liming Lu, Jingwen Ruan, and Guihua Wen revised the manuscript. Pei Yang, Xiaozhou Lv, and Boyu Jiao will plan the data analysis. Liqian Cui, Yingshuo Yan, Fanqi Meng,

Guanheng He, and Xin Zhou will participate in participant recruitment. All authors discussed, read, and revised the manuscript, and all approved the publication of this protocol.

Funding: The study was supported by the Key R&D Program of Guangdong Province (2020B1111120001).

Competing interests: None declared.

Patient consent for publication: Not applicable

Provenance and peer review: Not commissioned; externally peer-reviewed.

Ethics statements

Patient consent for publication

Not applicable.

Ethics approval and consent to participate: The study was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sun University (2021763). Participants will be included only after they provide written informed consent. The study was registered in the Chinese Clinical Trial Registry (No.ChiCTR2100052502, 30/10/2021).

References

1. Punnoose AR, Golub RM, Burke AE. JAMA patient page. Insomnia. JAMA 2012;307(24):2653.

Merrigan JM, Buysse DJ, Bird JC, et al. JAMA patient page. Insomnia. JAMA 2013;309(7):733.

3. Roth T. Insomnia: Definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007;3(Suppl 5):S7–10.

 Kalmbach DA, Anderson JR, Drake CL. The impact of stress on sleep: Pathogenic sleep reactivity as a vulnerability to insomnia and circadian disorders. J Sleep Res 2018; 27(6):e12710.

5. Shekleton JA, Flynn-Evans EE, Miller B, et al. Neurobehavioral performance impairment in insomnia: relationships with self-reported sleep and daytime functioning. Sleep 2014;37(1):107–16.

6. Cross NE, Carrier J, Postuma RB, et al. Association between insomnia disorder and cognitive function in middle-aged and older adults: A cross-sectional analysis of the Canadian Longitudinal Study on Aging. Sleep 2019;42(8).

7. Singareddy R, Vgontzas AN, Fernandez-Mendoza J, et al. Risk factors for incident chronic insomnia: A general population prospective study. Sleep Med 2012;13(4):346–53.

8. Zhang Y, Ren R, Lei F, et al. Worldwide and regional prevalence rates of co-occurrence of insomnia and insomnia symptoms with obstructive sleep apnea: A systematic review and meta-analysis. Sleep Med Rev 2019;45:1–17.

9. Kessler RC, Berglund PA, Coulouvrat C, et al. Insomnia, comorbidity, and risk of injury among insured Americans: Results from the America Insomnia Survey. Sleep 2012;35(6):825–34.

10. Kalmbach DA, Cheng P, Arnedt JT, et al. Improving daytime functioning, work performance, and quality of life in postmenopausal women with insomnia: comparing cognitive behavioral therapy for insomnia, sleep restriction therapy, and sleep hygiene education. J Clin Sleep Med 2019;15(7):999–1010.

11. Espie CA, Emsley R, Kyle SD et al. Effect of digital cognitive behavioral therapy for insomnia on health, psychological well-being, and sleep-related quality of life: a randomized clinical trial. JAMA Psychiatry 2019;76(1):21–30.

BMJ Open

12. Thakral M, Von Korff M, McCurry SM, et al. Changes in dysfunctional beliefs about sleep after cognitive behavioral therapy for insomnia: A systematic literature review and meta-analysis. Sleep Med Rev 2020;49:101230.

13. Garland SN, Xie SX, DuHamel K, et al. Acupuncture versus cognitive behavioral therapy for insomnia in cancer survivors: a randomized clinical trial. J Natl Cancer Inst 2019;111(12):1323–31.

14. Liou KT, Root JC, Garland SN, et al. Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial. Cancer 2020;126(13):3042–52.

15. Xing J, Wu X, Liu H, et al. Effects of electroacupuncture therapy and cognitive behavioral therapy in chronic insomnia: a randomized controlled study. Evid Based Complement Alternat Med 2020;5630130.

16. Liqian C, Jingwen R, Minying Z, et al. Effects of acupuncture combined with cognitive behavioral therapy on sleep quality, sleep belief and attitude in patients with chronic insomnia. Guangdong Medical Journal 2020;41(10):1005–9.

17. Ruan JW, Wang CH, Liao XX, et al. Electroacupuncture treatment of chronic insomniacs. Chin Med J 2009;122(23):2869–73.

Freire AO, Sugai GC, Togeiro SM, et al. Immediate effect of acupuncture on the sleep pattern of patients with obstructive sleep apnoea. Acupunct Med 2010;28(3):115–9.
 Gorban AN, Makarov VA, Tyukin IY. The unreasonable effectiveness of small neural ensembles in high-dimensional brain. Phys Life Rev 2019;29:55–88.

20. Bresch E, Großekathöfer U, Garcia-Molina G. Recurrent deep neural networks for real-time sleep stage classification from single channel EEG. Front Comput Neurosci 2018;12:85.

21. Hassan AR, Bhuiyan MIH. Automated identification of sleep states from EEG signals by means of ensemble empirical mode decomposition and random under sampling boosting. Comput Methods Programs Biomed 2017;140:201–10.

22. Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.

23. MacPherson H, Altman DG, Hammerschlag R, et al. Revised Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. J Evid Based Med 2010;3(3):140–55.

24. Wang C, Yang WJ, Yu XT, et al. Acupuncture for insomnia with short sleep duration: protocol for a randomised controlled trial. BMJ Open 2020;10(3):e033731.

25. Battle DE. Diagnostic and Statistical Manual of Mental Disorders (DSM). CoDAS 2013;25(2):191–2.

26. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest 2014;146(5):1387–94.

27.Qaseem A, Kansagara D, Forciea MA, et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2016;165(2):125–33.

28. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28(2):193–213.

29. Mollayeva T, Thurairajah P, Burton K, et al. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: a systematic review and meta-analysis. Sleep Med Rev 2016;25:52–73.

30. Robinson BE, Kelley L: Concurrent validity of the Beck Depression Inventory as a measure of depression. Psychol Rep 1996;79(3 Pt 1):929–30.

31. Piotrowski C: Use of the Beck Depression Inventory in clinical practice. Psychol Rep 1996;79(3 Pt 1):873–4.

32. Carney CE, Ulmer C, Edinger JD, et al. Assessing depression symptoms in those with insomnia: an examination of the Beck depression inventory second edition (BDI-II). J Psychiatr Res 2009;43(5):576–82.

BMJ Open

33. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56(6):893–7.

34. Nyer M, Farabaugh A, Fehling K, et al. Relationship between sleep disturbance and depression, anxiety, and functioning in college students. Depress Anxiety 2013;30(9):873–80.

35. Morin CM, Vallières A, Ivers H. Dysfunctional beliefs and attitudes about sleep (DBAS): Validation of a brief version (DBAS-16). Sleep 2007;30(11):1547–54.

36. Chung KF, Ho FY, Yeung WF. Psychometric comparison of the full and abbreviated versions of the dysfunctional beliefs and attitudes about sleep scale. J Clin Sleep Med 2016;12(6):821–8.

37. Ramaswamy SM, Weerink MAS, Struys M, et al. Dexmedetomidine-induced deep sedation mimics non-rapid eye movement stage 3 sleep: Large-scale validation using machine learning. Sleep 2021;44(2).

38. Abou Jaoude M, Sun H, Pellerin KR, et al. Expert-level automated sleep staging of long-term scalp electroencephalography recordings using deep learning. Sleep 2020;43(11).

39. Malhotra RK, Kirsch DB, Kristo DA, et al. Polysomnography for obstructive sleep apnea should include arousal-based scoring: An American Academy of Sleep Medicine position statement. J Clin Sleep Med 2018;14(7):1245–7.

40. Zhang P, Zhao Z. Interpretation of "Guidelines for the diagnosis and treatment of adult insomnia in China." Chin J Contemp Neurol Neurosurg 2013;13(5):363–7.

41. Wilt TJ, MacDonald R, Brasure M, et al. Pharmacologic treatment of insomnia disorder: An evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med 2016;165(2):103–12.

42. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017;26(6):675–700.

43. Kathol RG, Arnedt JT. Cognitive behavioral therapy for chronic insomnia: Confronting the challenges to implementation. Ann Intern Med 2016;165(2):149–50.

44. Ree M, Junge M, Cunnington D. Australasian Sleep Association position statement regarding the use of psychological/behavioral treatments in the management of insomnia in adults. Sleep Med 2017;Suppl 36(1):S43–7.

45. Coutaux A. Non-pharmacological treatments for pain relief: TENS and acupuncture. Joint bone spine 2017;84(6):657–61.

46.Iravani S, Kazemi Motlagh AH, Emami Razavi SZ, et al. Effectiveness of acupuncture treatment on chemotherapy-induced peripheral neuropathy: A pilot, randomized, assessor-blinded, controlled trial. Pain Res Manag 2020;2504674.

47.Zhang L, Fabbri D, Upender R, et al. Automated sleep stage scoring of the Sleep Heart Health Study using deep neural networks. *Sleep* 2019;42(11).

48.Kempfner J, Sorensen GL, Sorensen HB, et al. Automatic REM sleep detection associated with idiopathic rem sleep Behavior Disorder. Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference 2011:6063-6066.


49.Lajnef T, Chaibi S, Ruby P, et al. Learning machines and sleeping brains: Automatic sleep stage classification using decision-tree multi-class support vector machines. Journal of neuroscience methods 2015;250:94-105.

50. Qu W, Wang Z, Hong H, et al. A Residual Based Attention Model for EEG Based Sleep Staging. IEEE journal of biomedical and health informatics 2020;24(10):2833-2843.

51.Wang Y, Loparo KA, Kelly MR, et al. Evaluation of an automated single-channel sleep staging algorithm. Nature and science of sleep 2015;7:101-111.

52.Stepnowsky C, Levendowski D, Popovic D, et al. Scoring accuracy of automated sleep staging from a bipolar electroocular recording compared to manual scoring by multiple raters. Sleep medicine 2013; 14(11):1199-1207.

1	
1 2 3 4 5 6 7 8 9	Fig 1. CONSORT 2010 Flow Diagram
10 11 12 13 14 15 16 17	
18 19 20 21 22 23 24 25	
26 27 28 29 30 31 32 33	
34 35 36 37 38 39 40 41	
42 43 44 45 46 47 48 49	
50 51 52 53 54 55 56 57	
57 58 59	For peer review only - http://bmiopen.bmi.com/site/about/guidelines.xhtm



Page	23 of 28	BMJ Open		
1 2 3 4 5 6 7			BMJ Open SPRICE SPRICE STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS ommended items to address in a clinical trial protocol and related documents*	
8 9 10 11	Section/item	ltem No	Description Image: Section and the section of the	Addressed on page number
12 13 14	Administrative inf	ormatior		
15 16 17	Title	1	Descriptive title identifying the study design, population, interventions, and, if applicate, trial acronym	<u>1</u>
18 19	Trial registration	2a		<u>1</u>
20 21 22 23		2b	Trial identifier and registry name. If not yet registered, name of intended registry All items from the World Health Organization Trial Registration Data Set Date and version identifier	<u>1</u>
	Protocol version	3	Date and version identifier	<u>1</u>
24 25	Funding	4	Sources and types of financial, material, and other support	<u>12</u>
26 27	Roles and	5a	Names, affiliations, and roles of protocol contributors	<u>1,12</u>
28 29	responsibilities	5b	Name and contact information for the trial sponsor	<u>12</u>
30 31 32 33 34		5c	Role of study sponsor and funders, if any, in study design; collection, management, a all all sis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	<u>12</u>
34 35 36 37 38 39 40 41 42		5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups over seeing the trial, if applicable (see Item 21a for data monitoring committee)	<u>NA</u>
43 44 45 46			₽ For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

24

			BMJ Open BMJ Open 20	
	Introduction		-2022-06	
	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	<u>3-4</u>
		6b	Explanation for choice of comparators	<u>5</u>
	Objectives	7	Specific objectives or hypotheses	<u>4</u>
) 2 3	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factoriat, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	<u>4</u>
4 5	Methods: Participa	nts, inte	erventions, and outcomes	
5 7 3	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	<u>4-5</u>
)) 	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	<u>6</u>
2 3 4	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	<u>6-7</u>
5 7 3		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	<u>6</u>
)) 		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	<u>6</u>
<u>2</u> 3		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	<u>6</u>
4 5 7 3	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	<u>7-9</u>
) <u>2</u>	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) $\frac{3}{2}$	4,Table 1,Figure 1
3 4 5			금 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 25 of 28			BMJ Open		
1 2 3 4 5	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations		
	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	<u>8-9</u>	
6 7	Methods: Assignm	mterventions (for controlled trials) 명 명 영문			
8 9	Allocation:		and the second sec	<u>5</u>	
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	<u>5</u>	
	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequent ally numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	<u>5</u>	
	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	<u>5</u>	
	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care proveders, outcome assessors, data analysts), and how	<u>5</u>	
20 27 28 29		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	<u>5</u>	
30 31	Methods: Data collection, management, and analysis				
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	<u>9</u>	
		18b	Plans to promote participant retention and complete follow-up, including list of any our come data to be collected for participants who discontinue or deviate from intervention protocols For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	<u>9</u>	

			프 BMJ Open 우 막	
1 2 3 4 5 6 7	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>9-10</u>
	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>9-10</u>
8 9		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>9-19</u>
10 11 12 13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>9-10</u>
14 15	Methods: Monitorir	ng		
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>9-10</u>
		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>9-10</u>
	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously geported adverse events and other unintended effects of trial interventions or trial conduct	<u>9-10</u>
	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>9-10</u>
32 33	Ethics and dissemi	nation	2024 by g	
34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) ap	<u>5</u>
37 38 39 40 41 42	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility contents, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial participants, trial registries, journals, regulators)	NA
43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page	27	of	28
------	----	----	----

Page 27 of 28			BMJ Open			
1 2	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)		<u>6</u>	
3 4 5 6		26b	Additional consent provisions for collection and use of participant data and biological specimens ancillary studies, if applicable \Im_{Θ}^{\sharp}	in	<u>6</u>	
7 8 9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial		<u>6</u>	
10 11 12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site		<u>12</u>	
13 14 15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contracted al agreements that limit such access for investigators		<u>6</u>	
16 17 18 19	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harn from trial participation	n	<u>6</u>	
20 21 22 23	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions		<u>6</u>	
24 25		31b	Authorship eligibility guidelines and any intended use of professional writers		<u>6</u>	
26 27 28 29		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistica code	al	<u>6</u>	
30 31	Appendices		3, 202			
32 33	Informed consent	32	Model consent form and other related documentation given to participants and authous	See	The	Ethics
34 35 36	materials		surrogates generation of the surrows genera	Appro	oval Doc	<u>cument</u>
37 38 39 40	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for generatic or molecular analysis in the current trial and for future use in ancillary studies, if applicable		<u>NA</u>	
40 41 42 43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml			

mjopen-2 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons An http://bmjopen.bmj.com/ on April 18, "Attribution-NonCommercial-NoDerivs 3.0 Unported" license. 42 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Acupuncture combined with cognitive-behavioral therapy for insomnia (CBT-I) in patients with insomnia: study protocol for a randomized controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-063442.R1
Article Type:	Protocol
Date Submitted by the Author:	16-Oct-2022
Complete List of Authors:	Pei, Wenya; Sun Yat-sen University First Affiliated Hospital He, Te; South China University of Technology Yang, Pei; South China University of Technology Lv, Xiaozhou; Sun Yat-sen University First Affiliated Hospital Jiao, Boyu; Sun Yat-sen University First Affiliated Hospital Meng, Fanqi; Sun Yat-sen University First Affiliated Hospital Yan, Yingshuo; Sun Yat-sen University First Affiliated Hospital Cui, Liqian; Sun Yat-sen University First Affiliated Hospital He, Guanheng; Sun Yat-sen University First Affiliated Hospital Zhou, Xin; Sun Yat-sen University First Affiliated Hospital Wen, Guihua; South China University First Affiliated Hospital Wen, Jingwen; Sun Yat-sen University First Affiliated Hospital Lu, Liming; Guangzhou University of Chinese Medicine
Primary Subject Heading :	Complementary medicine
Secondary Subject Heading:	Health services research, Neurology, Public health
Keywords:	CLINICAL PHYSIOLOGY, Rehabilitation medicine < INTERNAL MEDICINE, COMPLEMENTARY MEDICINE, REHABILITATION MEDICINE

SCHOLARONE[™] Manuscripts

Acupuncture combined with cognitive-behavioral therapy for insomnia (CBT-I) in patients with insomnia: study protocol for a randomized controlled trial

Wenya Pei¹, Te He², Pei Yang², Xiaozhou Lv³, Boyu Jiao¹, Fanqi Meng¹, Yingshuo Yan⁴, Liqian Cui⁵, Guanheng He¹, Xin Zhou¹, Guihua Wen², Jingwen Ruan¹, Liming Lu⁶

¹Department of Acupuncture, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

² School of Computer Science and Engineering, South China University of Technology, Guangzhou, China

³Department of Traditional Chinese Medicine, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China

⁴Department of Respiratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

⁵Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China ⁶South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China.

Corresponding author:

Liming Lu. South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China. Email: lulimingleon@126.com

Jingwen Ruan. Department of Acupuncture, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Email: ruanjw@163.com

Guihua Wen. School of Computer Science and Engineering, South China University of

Technology, Guangzhou, China. Email: crghwen@scut.edu.cn

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Abstract

Introduction

Insomnia affects physical and mental health due to the lack of continuous and complete sleep architecture. Polysomnograms (PSGs) are used to record electrical information to perform sleep architecture using deep learning. Acupuncture combined with cognitive-behavioral therapy for insomnia (CBT-I) could not only improve sleep quality, solve anxiety, depression but also ameliorate poor sleep habits and detrimental cognition. However, the mechannism of clinical study in this process remain unclear.

Methods and analysis

This randomized controlled trial will evaluate the efficacy and effectiveness of electroacupuncture combined with CBT-I in patients with insomnia. Participants will be randomized to receive either electroacupuncture combined with CBT-I or sham acupuncture and followed up for four weeks. The primary outcome is sleep quality, which is evaluated by the Pittsburgh sleep quality index(PSQI). The secondary outcome measures include a measurement of depression severity, anxiety, maladaptive cognitions associated with sleep, and adverse events. Sleep architecture will be assessed using deep learning on PSGs.

Ethics and dissemination

This trial has been approved by the institutional review boards and ethics committees of the First Affiliated Hospital of Sun Yat-sun University (2021763). The results will be disseminated through peer-reviewed journals.

Trial registration number

CTR2100052502

Keywords: insomnia, cognitive behavioral therapy for insomnia, electroacupuncture, randomized controlled trial

Strengths and limitations of this study

- This study will investigate the efficacy and effectiveness of electroacupuncture combined with CBT-I in patients with insomnia.
- A randomized controlled trial will be conducted to assess sleep quality, depression severity, anxiety, maladaptive cognitions associated with sleep, and adverse events.
- Deep learning will be used to observe the effects of electroacupuncture combined with CBT-I on sleep architecture in different dimensions.
- Using deep learning, this study will develope a high-performing, reference channel-free, automated sleep staging algorithm to analyze the sleep architecture.
- We will provide an insight into the combined application of electroacupuncture and CBT-I for insomnia in the clinic



BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Introduction

Insomnia is characterized by difficulties in initiating or maintaining sleep or impaired daytime functioning, which impact both physical and mental health^[1-3]. The lack of continuous and complete sleep architecture due to long-term fragmented and light sleep in patients with insomnia causes a decrease in sleep quality, which affects daily functions, and even induces anxiety, depression, and other mental symptoms^[4-6]. With the increasing pressures in daily life and work, insomnia is becoming a public health problem that needs to be solved urgently as it worsens the quality of life of patients, burdens caregivers, and increases social and economic costs^[7-9].

Cognitive-behavioral therapy for insomnia (CBT-I) is recommended as first-line treatment for insomnia and may improve sleep quality and alleviate poor sleep cognition in patients with insomnia^[10-12]. During the early stage of treatment, the sleep quality of patients with severe anxiety were improved slowly and the compliance of these patients were poor. Thus, as confirmed in previous studies, acupuncture combined with CBT-I could not only solve anxiety, depression, and other emotions caused by insomnia but also ameliorate poor sleep habits and detrimental cognition^[13-16].

However, there is a lack of rigorous clinical evidence on the treatment of insomnia with acupuncture combined with CBT-I; moreover, the clinical mechanism is unclear. In previous studies, we found that by analyzing polysomnograms(PSGs), electroacupuncture improves sleep architecture and prolongs the duration of slow-wave and rapid-eye-movement (REM) sleep^[17-19]. But whether acupuncture combined with CBT-I improves sleep architecture requires futher research.

During the past decade, the application of deep learning to automatic sleep staging using PSGs has shown promise for understanding the macrostructure of sleep. Deep learning allows the automatic extraction of features from data related to classification tasks, and the performance of deep neural networks continues to improve as the size of the dataset increases^[20-22].

Page 5 of 31

BMJ Open

Using a high-performance automatic sleep staging algorithm to analyze PSGs recordings via deep learning, this study will focus on the effects of electroacupuncture combined with CBT-I on sleep architecture, sleep quality, and sleep attitudes and beliefs in patients with insomnia. Furthermore, this research will provide guidance for electroacupuncture combined with CBT-I using artificial intelligence.

Methods

Study design

The study will be an assessor-blinded, randomized controlled trial. The protocol was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sun University (2021763). We will follow the Consolidated Standards of Reporting Trials and Standards for Reporting Interventions in Clinical Trials of Acupuncture guidelines for the design and reporting of the trial^[23, 24]. The flowchart of the trial is presented in Figure 1, and the schedule of enrolment, interventions, and outcome assessments are presented in Table 1.

Sample size calculations: Referring to the previous litetature^[25], we assume that the expected PSQI value and determine that an alpha level of 0.05, which would allow us to detect a difference in PSQI score between the two groups. Allowing for a 15% dropout rate, a sample size of 36 in each group is sufficient to meet statistical requirements.

Randomization, allocation, and blinding

Patients who are interested in participating in the trial will initially be screened by phone and then asked to participate in a face-to-face interview to conduct further surveys. After recruiting all participants, random numbers will be generated and assigned by a central randomization system of the Clinical Research and Data Center of Guangzhou University of Chinese Medicine. The researcher who will screen the eligible patients after baseline

BMJ	Open
-----	------

			AJ Open	urt	36/bmjopen-2022-063442 o	Ρ
	Screening		Observation pha	ise	ع Follow-up∯hase	
Project	assession 0 pre-treament	Assession 1 pre-treament	Assession 2 Week 2±1day	Assession 3 Week 4±2day	Assession 4 Week 8±2 day	Unplanned follow-up
Medical history collection	\checkmark	-	-	-	er 2022.	
Sign the informed consent form	\checkmark	-	-	-	- D	
Inclusion criteria	\checkmark	-	-	-	ownld	
Exclusion criteria	\checkmark	0 -	-	-	- ec	
Basic Information	\checkmark		-	-	d fron	
Vital signs	\checkmark	V		\checkmark	√ I	*
Index of laboratory inspection	*	*	×	*	Downloaded from http://bmjopen.bmj.com/ on April 18, \sim \sim \sim \sim \sim \sim \sim \sim \sim \sim	
PSG	-	\checkmark		\checkmark	- jopei	
Pittsburgh sleep quality index(PSQI)	-	\checkmark	V	\checkmark	√ bmj	
Beck depression inventory(BDI)	-	\checkmark	V	\checkmark	√ com	
Beck anxiety inventory(BAI)		\checkmark		\checkmark	√on	
DBAS-16	-	\checkmark		\checkmark	-√ ^{April}	
Adverse Events	-	*	*	*	×18, 2	*
Medication records	-	\checkmark		\checkmark	2024 by gu¢ ≪ → ※	
Terminate test evaluation	-	*	*	*	ي م	

Notes: "X"Record when necessary; PSG: Long-term scalp electroencephalogram recording; DBAS-16: Dysfunctional Belefs and Attitudes about Sleep Scale 16 versio

will assign patients to either the treatment or control group. Researchers, which include statisticians, outcome assessors, and data analysts, will all be blinded to patients' group assignments. Although acupuncturists will be not blinded to group assignment, they will not be involved in outcome assessments or data analyses. In addition, all researchers will undergo training for specific procedures before the trial begins.

Participants and recruitment

Patients will be recruited using hospital-based advertisements in the Department of Acupuncture and Department of Neurology of the First Affiliated Hospital of Sun Yat-sen University from January 1,2022 to December 30,2025.

The inclusion criteria will be as follows: (1) meets diagnostic criteria for insomnia based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition^[26] and the International Classification of Sleep Disorders, Third Edition^[27], (2) aged 18–65 years, (3) experienced insomnia for more than 1 month but less than 2 years before the start of the trial, (4) voluntarily agrees to participate in the investigation and provides written informed consent before the clinical trial starts.

The exclusion criteria will be as follows: (1) serious cardiovascular, liver, kidney, or hematopoietic system disease, (2) insomnia was caused by a nervous system disease (e.g., stroke or Parkinson's disease), (3) insomnia was caused by a mental disorder, such as depression or anxiety, (4) history of sleep apnea, (5) pregnant or lactating women, (6) have received or currently receiving CBT-I.

Withdrawal criteria will be as follows: (1) patient withdrawal from the trial because of personal reasons, (2) patient has an adverse reaction related to acupuncture and refuses to continue treatment, (3) during the follow-up period, the patient cannot be contacted because of change of address and telephone number.

Intervention

The intervention will begin the day following randomization. All participants will receive 20 times treatments (five times per week for 4 weeks).

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Observation group

Acupuncture treatment

Patients' skin will be disinfected with 75% alcohol, and patients will be asked to lie supine and wear eye masks for a better curative effect. Each participant will receive acupuncture treatment from the same acupuncturist who has more than 5 years of clinical experience in acupuncture therapy. The temperature of the treatment room will not be lower than 25°C.

Patients in the acupuncture group will receive electroacupuncture treatment on Sishenchong (EX-HN1), bilateral Neiguan (PC6), bilateral Taixi (KI3), bilateral Shenmen (HT7), and bilateral Sanyinjiao (SP6)^[16]. Tube-guided acupuncture needles will be inserted to a depth of 17-25 mm at each acupoint (acupuncture location and method for each acupoint are provided in Table 2 and Figure 2). A low-frequency electronic pulse therapy instrument (G6805-2A, Shanghai Huayi Medical Instrument Co, Shanghai, China) will be used with 10-Hz continuous waves, and the current will range from 1 to 5 mA which will be adjusted based on the tolerance of each patient.

CBT-I treatment

CBT-I will be given while acupuncture treatment is in progress. The intervention will consist of behavioral components (e.g. sleep restriction and stimulus control), cognitive components (e.g., cognitive restructuring and paradoxical intention), progressive muscle relaxation, and sleep hygiene^[28].

Control group

The procedure for the control group will be the same as that for the observation group with no CBT-I treatment. The major difference in interventions between the two groups being the tube needling method, in which no needle will be inserted through the tube for patients in the control group. To mimic the sensation of a real needle being inserted into the body, the acupuncturist will place the tube close to the skin at the acupoint and tap the top of the tube.

Quality control

The trial will be conducted under the supervision of the First Affiliated Hospital of Sun Yat-sun University. A qualified clinical trial expert will be invited to monitor the study to identify problems during the trial, examine collected data, and control bias.

Outcome measures

Primary outcome

Pittsburgh sleep quality index

The Pittsburgh sleep quality index (PSQI) is an internationally established tool that is used to evaluate sleep quality. The scale includes seven dimensions that consist of subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, sleeping medication, and daytime dysfunction. The score correlates adversely with sleep quality which a higher score means the sleep quality is worse, and each factor has a score of 0 to 3 to provide a total score of 21 points^[29, 30].

Secondary outcomes

The Beck depression inventory

The Beck depression inventory (BDI) is a valid self-assessment index to measure depression severity and consists of 13 items. Each item is scored from 0 to 3 (0 to 4 indicates no depression, 5 to 7 indicates mild depression, 8 to 15 indicates moderate depression), with a score of 16 points or more considered as severe depression^[31-33].

The Beck anxiety inventory

The Beck anxiety inventory (BAI) is used to assess the degree of anxiety and consists of 21 items scored from 1 to 4 (15 to 25 points indicates mild anxiety, 26 to 35 points indicates moderate anxiety, and 36 points is considered severe anxiety)^[34, 35].

Other Outcomes

The Dysfunctional Beliefs and Attitudes about Sleep Scale 16 version

The Dysfunctional Beliefs and Attitudes about Sleep Scale 16 version (DBAS-16) is used to evaluate maladaptive cognitions associated with sleep. There are 16 items in the index,

	BMJ Open	n acupoint
	Table 2 Acupuncture location and method for each	n acupoint
Acupoint	Location	Needling method
Sishenchong (EX-HN1)	On the parietal region, 1 cun anterior ,posterior and lateral to Baihui, 4 acpoints totally.	The angle between the needle tip and the scalp is 30_{\circ} . Move the needle tip backward along the anterioreposterio midline, and then mesert the needle 0.5 cun.
Neiguan(PC6)	On the line joining Daling and Quze, between the tendons of palmaris longus and flexor carpi radialis, 2 cun above the transverse crease of the wrist.	Puncture perpendi gularly 1-1.5 cun.
Taixi (KI3)	In the depression between the tip of the medial malleolus and the Achilles tendon.	Puncture perpendicularly 0.5-1 cun.
Shenmen (HT7)	On the palmar ulnar end of the transverse crease of the wrist, and on the radial aspect of the tendon of the ulnar flexor m. of the wrist.	Puncture perpendicularly 0.5-1 cun.
Sanyinjiao (SP6)	Posterior to the mesial border of the tibia, and 3 cun above the tip of the medial malleolus	<u>-</u> -
	For peer review only - http://bmjopen.bmj.com/site/about/gui	18, 2024 by guest. Protected by copyright. delines.xhtml

BMJ Open

which are divided into four factors comprising consequences of insomnia, worry about sleep, sleep expectations, and medication. These factors are scored on a scale of 1-5(strongly disagree to strongly agree). The total score is positively correlated with the reasonableness of sleep beliefs and attitudes^[36, 37].

Sleep staging

The PARADISEP&D9600 (U.S.) Polysomnography Monitoring and Analysis System will be used to simultaneously monitor EEG, EOG, and EMG. A large clinical dataset of PSG recordings will be used to train a hybrid convolutional neural network (CNN) and recurrent neural network (RNN) to learn effective and generalizable features for sleep stage scoring^[38, 39]. Then clinical data will be used to indentify the deep learning algorithm. Sleep staging for both datasets will be performed by expert sleep technicians in nonoverlapping 30-s epochs according to standards by the American Academy of Sleep Medicine(AASM), as one of five stages: wake(W), non-rapid eye movement(REM) stage 1(N1), non-REM stage 2(N2), non-REM stage 3(N3), and rapid eye movement (REM)^[40].

Adverse events

During treatment and four week after treatment, a questionnaire will be administered to evaluate the various discomforts that may be caused by acupuncture: hangover, addiction, tolerance, fatigue after waking, insomnia rebound, daytime alertness, cognitive function, and behavior ability.

Patients and public involvement

Patients and the public are not involved in the design or conduct of the study or the outcome measures, and no attempt will be made to assess the burden of the intervention on the patients themselves. The results of this study will be disseminated to study participants via the website of our hospitals.

Statistical analysis

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

All analyses will be performed on the intention-to-treat population of participants who had at least one treatment. Missing data will be replaced according to the principle of the last observation carried forward. Data analyses will be performed using the SPSS version 25 (IBM Corp.) software. All available data will be analyzed descriptively. For continuous data, the normality test will be applied at the beginning of the analysis. Results will be presented as means, standard deviations, and 95% confidence intervals (CIs) for continuous data that conform to the normal distribution and medians, quartiles, and ranges for rank data and continuous data that are not normally distributed. Discrete data will be presented as percentages.

We will first examine the descriptive data for sample characteristics at baseline, and independent samples t-tests will be used to compare groups for continuous variables, whereas chi-square analysis will be used to compare groups for dichotomous variables. Second, we will perform two series of repeated-measures and univariate analyses of covariance (ANCOVA) models to examine treatment effects. We will use repeated-measures ANCOVAs to analyze the primary and secondary outcome measures (i.e., PSQI, BDI, BAI, DBAS-16, and sleep staging scores) from pre-treatment to post-treatment. If a significant effect is observed, we will conduct posthoc paired samples t-tests to examine within-group changes in study outcomes. For all study outcomes, we will then perform univariate ANCOVAs to test for group differences in post-treatment values while controlling for relevant covariates. This process will be repeated to examine changes in study outcomes from pre-treatment to postnatal follow-up.

When necessary, ITT analysis and sensitivity analysis will be used to assess the robustness of the conclusions of the entire clinical trial. To evaluate the consistency of the trial and explore the factors that affect efficacy or prognosis, subgroup analysis will be conducted to identify the population with better efficacy. Safety analysis will be used to assess the incidence of adverse events and related symptoms in patients with insomnia during treatment and follow-up.

Discussion

Currently, the main treatments recommended for insomnia are non-pharmaceutical and pharmaceutical treatments. Pharmaceutical treatments include benzodiazepines as well as new non-benzodiazepine drugs, which can shorten the latency to fall asleep and prolong total sleep time but also affect normal sleep physiology and cause adverse reactions^[41, 42]. CBT-I, which is recommended as a first-line treatment for insomnia by the European insomnia guidelines, is limited in clinical practice because of insufficient professional therapists and poor compliance of patients with insomnia, especially in developing countries such as China^[42-45].

As a complementary alternative therapy with a long history in China, acupuncture has been used as a clinical treatment for insomnia with fewer adverse effects and less permanent damage. Previous studies showed that either acupuncture or CBT-I could produce clinically meaningful improvements in insomnia symptoms, and our preliminary research have confirmed that acupuncture combined with CBT-I also alleviate not only insomnia symptoms but also negative emotions such as anxiety and depression^[13, 14, 16]. But whether acupuncture combined with CBT-I could influence sleep habits and correct cognition, and what the clinic clinical mechanism worth futher research.

To ameliorate sleep habits, correct cognition, and alleviate anxiety, depression, and other emotions caused by insomnia, this study will use electroacupuncture combined with CBT-I and observe sleep architecture, sleep quality, and sleep attitudes and beliefs in patients with insomnia. In this study, PSQI will be used to assess the sleep quality, BDI and BAI will be used to evaluate the depression severity and anxiety. At the same time, we will use DBAS-16 to evaluate the sleep beliefs and attitudes before and after treatment. Because of the particularity of acupuncture therapy, the implementation of blinding is difficult in clinical research^[46, 47]. A research team composed of researchers, therapists, testers, and statisticians will be established to reduce any bias that may occur

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

during the research process by blinding testers and statisticians. This study will provide clinical evidence for the effect and safety of electroacupuncture combined with CBT-I and provide a decision-making reference for clinicians, patients, and policymakers.

To analyze the effects of electroacupuncture combined with CBT-I on sleep architecture and sleep quality in patients with insomnia, deep learning will be used to analyze PSGs in various clinical settings in this study. PSGs are used widely for clinical evaluation because they are more sensitive than routine EEGs (typically 30–60 min duration) in capturing paroxysmal electrical abnormalities^[48, 49]. During the past decade, there have been various advances in automated sleep staging of PSGs data using the ability of deep learning methods to automatically extract features from data that are relevant to the classification; moreover, the performance of deep neural networks continues to improve as datasets become larger^[50-52]. Using deep learning, this study will develope a high-performing, reference channel-free, automated sleep staging algorithm to analyze the sleep architeture which will provide a clinical mechanism in artificial intelligence.

In summary, this study will use electroacupuncture combined with CBT-I to treat insomnia and observe the sleep beliefs and attitudes of patients with insomnia in different dimensions using deep learning. Moreover, we will provide a solid research basis for the combined application of electroacupuncture and CBT-I for insomnia in the clinic.

Acknowledgments Not applicable.

Footnotes

Contributors: Wenya Pei and Te He designed the trial protocol and drafted the manuscript. Liming Lu, Jingwen Ruan, and Guihua Wen revised the manuscript. Pei Yang, Xiaozhou Lv, and Boyu Jiao will plan the data analysis. Liqian Cui, Yingshuo Yan, Fanqi Meng,

Guanheng He, and Xin Zhou will participate in participant recruitment. All authors discussed, read, and revised the manuscript, and all approved the publication of this protocol.

Funding: The study was supported by the Key R&D Program of Guangdong Province (2020B1111120001).

Competing interests: None declared.

Patient consent for publication: Not applicable

Provenance and peer review: Not commissioned; externally peer-reviewed.

Ethics and dissemination: The study was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sun University (2021763). Participants will be included only after they provide written informed consent. The study was registered in the Chinese 02, 36, Clinical Trial Registry (No.ChiCTR2100052502, 30/10/2021).

Ethics statements

Patient consent for publication

Not applicable.

References

1. Riemann D, Benz F, Dressle RJ, Espie CA, Johann AF, Blanken TF, Leerssen J, Wassing R, Henry AL, Kyle SD et al: Insomnia disorder: State of the science and challenges for the future. Journal of sleep research 2022, 31(4):e13604.

2. Chan WS, Levsen MP, McCrae CS: A meta-analysis of associations between obesity and insomnia diagnosis and symptoms. Sleep medicine reviews 2018, 40:170-182.

3. Wickwire EM: The Value of Digital Insomnia Therapeutics: What We Know and What We Need To Know. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2019, 15(1):11-13.

4. Kalmbach DA, Anderson JR, Drake CL: The impact of stress on sleep: Pathogenic sleep reactivity as a vulnerability to insomnia and circadian disorders. *Journal of sleep research* 2018, 27(6):e12710.

5. Shekleton JA, Flynn-Evans EE, Miller B, Epstein LJ, Kirsch D, Brogna LA, Burke LM, Bremer E, Murray JM, Gehrman P *et al*: Neurobehavioral performance impairment in insomnia: relationships with self-reported sleep and daytime functioning. *Sleep* 2014, 37(1):107-116.

6. Cross NE, Carrier J, Postuma RB, Gosselin N, Kakinami L, Thompson C, Chouchou F, Dang-Vu TT: Association between insomnia disorder and cognitive function in middle-aged and older adults: a cross-sectional analysis of the Canadian Longitudinal Study on Aging. *Sleep* 2019, 42(8).

7. Singareddy R, Vgontzas AN, Fernandez-Mendoza J, Liao D, Calhoun S, Shaffer ML, Bixler EO: Risk factors for incident chronic insomnia: a general population prospective study. *Sleep medicine* 2012, 13(4):346-353.

8. Zhang Y, Ren R, Lei F, Zhou J, Zhang J, Wing YK, Sanford LD, Tang X: Worldwide and regional prevalence rates of co-occurrence of insomnia and insomnia symptoms with obstructive sleep apnea: A systematic review and meta-analysis. *Sleep medicine reviews* 2019, 45:1-17.

9. Kessler RC, Berglund PA, Coulouvrat C, Fitzgerald T, Hajak G, Roth T, Shahly V, Shillington AC, Stephenson JJ, Walsh JK: Insomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia Survey. *Sleep* 2012, 35(6):825-834.

10. Kalmbach DA, Cheng P, Arnedt JT, Cuamatzi-Castelan A, Atkinson RL, Fellman-Couture C, Roehrs T, Drake CL: Improving Daytime Functioning, Work Performance, and Quality of Life in Postmenopausal Women With Insomnia: Comparing Cognitive Behavioral Therapy for Insomnia, Sleep Restriction Therapy, and Sleep

Hygiene Education. *Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine* 2019, 15(7):999-1010.

11. Espie CA, Emsley R, Kyle SD, Gordon C, Drake CL, Siriwardena AN, Cape J, Ong JC, Sheaves B, Foster R *et al*: Effect of Digital Cognitive Behavioral Therapy for Insomnia on Health, Psychological Well-being, and Sleep-Related Quality of Life: A Randomized Clinical Trial. *JAMA psychiatry* 2019, 76(1):21-30.

12. Thakral M, Von Korff M, McCurry SM, Morin CM, Vitiello MV: Changes in dysfunctional beliefs about sleep after cognitive behavioral therapy for insomnia: A systematic literature review and meta-analysis. *Sleep medicine reviews* 2020, 49:101230.

13. Garland SN, Xie SX, DuHamel K, Bao T, Li Q, Barg FK, Song S, Kantoff P, Gehrman P, Mao JJ: Acupuncture Versus Cognitive Behavioral Therapy for Insomnia in Cancer Survivors: A Randomized Clinical Trial. *Journal of the National Cancer Institute* 2019, 111(12):1323-1331.

14. Liou KT, Root JC, Garland SN, Green J, Li Y, Li QS, Kantoff PW, Ahles TA, Mao JJ: Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial. *Cancer* 2020, 126(13):3042-3052.

15. Xing J, Wu X, Liu H, Wang J, Jiang S, Lozada A, Wang Y: Effects of Electroacupuncture Therapy and Cognitive Behavioral Therapy in Chronic Insomnia: A Randomized Controlled Study. *Evidence-based complementary and alternative medicine : eCAM* 2020, 2020:5630130.

16. Cui L, Jingwen R, Minying Z, Guanheng H, Hao L: Effects of acupuncture combined with cognitive behavioral therapy on sleep quality, sleep belief and attitude in patients with chronic insomnia. *Guangdong Medical Journal* 2020, 41(10):1005-1009.

17. Ruan JW, Wang CH, Liao XX, Yan YS, Hu YH, Rao ZD, Wen M, Zeng XX, Lai XX: Electroacupuncture treatment of chronic insomniacs. *Chin Med J (Engl)* 2009, 122(23):2869-2873.

18. Yin X, Gou M, Xu J, Dong B, Yin P, Masquelin F, Wu J, Lao L, Xu S: Efficacy and safety of acupuncture treatment on primary insomnia: a randomized controlled trial. *Sleep medicine* 2017, 37:193-200.

19. Pei W, Peng R, Gu Y, Zhou X, Ruan J: Research trends of acupuncture therapy on insomnia in two decades (from 1999 to 2018):a bibliometric analysis. *BMC complementary and alternative medicine* 2019, 19(1):225.

20. Gorban AN, Makarov VA, Tyukin IY: The unreasonable effectiveness of small neural ensembles in high-dimensional brain. *Physics of life reviews* 2019, 29:55-88.

21. Bresch E, Großekathöfer U, Garcia-Molina G: Recurrent Deep Neural Networks for Real-Time Sleep Stage Classification From Single Channel EEG. *Frontiers in computational neuroscience* 2018, 12:85.

22. Hassan AR, Bhuiyan MIH: Automated identification of sleep states from EEG signals by means of ensemble empirical mode decomposition and random under sampling boosting. *Computer methods and programs in biomedicine* 2017, 140:201-210.

23. Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ (Clinical research ed)* 2010, 340:c332.

24. MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D: Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): Extending the CONSORT statement. *Journal of evidence-based medicine* 2010, 3(3):140-155.

25. Wang C, Yang WJ, Yu XT, Fu C, Li JJ, Wang J, Xu WL, Zheng YX, Chen XY, Chen YF: Acupuncture for insomnia with short sleep duration: protocol for a randomised controlled trial. *BMJ open* 2020, 10(3):e033731.

26. Battle DE: Diagnostic and Statistical Manual of Mental Disorders (DSM). *CoDAS* 2013, 25(2):191-192.

27. Sateia MJ: International classification of sleep disorders-third edition: highlights and modifications. *Chest* 2014, 146(5):1387-1394.

28. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD: Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. *Annals of internal medicine* 2016, 165(2):125-133.

29. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry research* 1989, 28(2):193-213.

30. Mollayeva T, Thurairajah P, Burton K, Mollayeva S, Shapiro CM, Colantonio A: The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and meta-analysis. *Sleep medicine reviews* 2016, 25:52-73.

31. Robinson BE, Kelley L: Concurrent validity of the Beck Depression Inventory as a measure of depression. *Psychological reports* 1996, 79(3 Pt 1):929-930.

32. Piotrowski C: Use of the Beck Depression Inventory in clinical practice. *Psychological reports* 1996, 79(3 Pt 1):873-874.

33. Carney CE, Ulmer C, Edinger JD, Krystal AD, Knauss F: Assessing depression symptoms in those with insomnia: an examination of the beck depression inventory second edition (BDI-II). *Journal of psychiatric research* 2009, 43(5):576-582.

34. Beck AT, Epstein N, Brown G, Steer RA: An inventory for measuring clinical anxiety: psychometric properties. *Journal of consulting and clinical psychology* 1988, 56(6):893-897.

35. Nyer M, Farabaugh A, Fehling K, Soskin D, Holt D, Papakostas GI, Pedrelli P, Fava M, Pisoni A, Vitolo O *et al*: Relationship between sleep disturbance and depression, anxiety, and functioning in college students. *Depression and anxiety* 2013, 30(9):873-880.

36. Morin CM, Vallières A, Ivers H: Dysfunctional beliefs and attitudes about sleep (DBAS): validation of a brief version (DBAS-16). *Sleep* 2007, 30(11):1547-1554.

37. Chung KF, Ho FY, Yeung WF: Psychometric Comparison of the Full and Abbreviated Versions of the Dysfunctional Beliefs and Attitudes about Sleep Scale. *Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine* 2016, 12(6):821-828.

38. Ramaswamy SM, Weerink MAS, Struys M, Nagaraj SB: Dexmedetomidine-induced deep sedation mimics non-rapid eye movement stage 3 sleep: large-scale validation using machine learning. *Sleep* 2021, 44(2).

39. Abou Jaoude M, Sun H, Pellerin KR, Pavlova M, Sarkis RA, Cash SS, Westover MB, Lam AD: Expert-level automated sleep staging of long-term scalp electroencephalography recordings using deep learning. *Sleep* 2020, 43(11).

40. Malhotra RK, Kirsch DB, Kristo DA, Olson EJ, Aurora RN, Carden KA, Chervin RD, Martin JL, Ramar K, Rosen CL *et al*: Polysomnography for Obstructive Sleep Apnea Should Include Arousal-Based Scoring: An American Academy of Sleep Medicine Position Statement. *Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine* 2018, 14(7):1245-1247.

41. Wilt TJ, MacDonald R, Brasure M, Olson CM, Carlyle M, Fuchs E, Khawaja IS, Diem S, Koffel E, Ouellette J *et al*: Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. *Annals of internal medicine* 2016, 165(2):103-112.

42. Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, Espie CA, Garcia-Borreguero D, Gjerstad M, Gonçalves M *et al*: European guideline for the diagnosis and treatment of insomnia. *Journal of sleep research* 2017, 26(6):675-700.

43. Kathol RG, Arnedt JT: Cognitive Behavioral Therapy for Chronic Insomnia: Confronting the Challenges to Implementation. *Annals of internal medicine* 2016, 165(2):149-150.

BMJ Open

44. Ree M, Junge M, Cunnington D: Australasian Sleep Association position statement regarding the use of psychological/behavioral treatments in the management of insomnia in adults. *Sleep medicine* 2017, 36 Suppl 1:S43-s47.

45. Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ, Lichstein KL, Sateia MJ, Troxel WM, Zhou ES, Kazmi U *et al*: Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. *Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine* 2021, 17(2):255-262.

46. Coutaux A: Non-pharmacological treatments for pain relief: TENS and acupuncture. *Joint bone spine* 2017, 84(6):657-661.

47. Iravani S, Kazemi Motlagh AH, Emami Razavi SZ, Shahi F, Wang J, Hou L, Sun W, Afshari Fard MR, Aghili M, Karimi M *et al*: Effectiveness of Acupuncture Treatment on Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized, Assessor-Blinded, Controlled Trial. *Pain research & management* 2020, 2020:2504674.

48. Zhang L, Fabbri D, Upender R, Kent D: Automated sleep stage scoring of the Sleep Heart Health Study using deep neural networks. *Sleep* 2019, 42(11).

49. Feige B, Baumgartner B, Meyer D, Riemann D: The Relationship Between PSG and Morning/Evening Emotional Parameters in Patients With Insomnia Disorder and Good Sleepers. *Frontiers in psychology* 2018, 9:2712.

50. Lajnef T, Chaibi S, Ruby P, Aguera PE, Eichenlaub JB, Samet M, Kachouri A, Jerbi K: Learning machines and sleeping brains: Automatic sleep stage classification using decision-tree multi-class support vector machines. *Journal of neuroscience methods* 2015, 250:94-105.


51. Qu W, Wang Z, Hong H, Chi Z, Feng DD, Grunstein R, Gordon C: A Residual Based Attention Model for EEG Based Sleep Staging. *IEEE journal of biomedical and health informatics* 2020, 24(10):2833-2843.


BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

52. Wang Y, Loparo KA, Kelly MR, Kaplan RF: Evaluation of an automated single-channel sleep staging algorithm. *Nature and science of sleep* 2015, 7:101-111.

м, inter.

Page 23 of 31	BMJ Open
Page 23 of 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59	БМ Open
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml





		BMJ Open B	
		BMJ Open Standard Protocol Items: Recommendations for Interventional Trials	
SPIRIT 2013 Check Section/item	list: Reco Item No	Description	Addressed on page number
Administrative inf	ormatior		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicate, trial acronym	<u>1</u>
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	<u>1</u>
	2b	Trial identifier and registry name. If not yet registered, name of intended registry All items from the World Health Organization Trial Registration Data Set Date and version identifier	1
Protocol version	3	Date and version identifier	<u>1</u>
Funding	4	Sources and types of financial, material, and other support	<u>12</u>
Roles and	5a	Names, affiliations, and roles of protocol contributors	<u>1,12</u>
responsibilities	5b	Name and contact information for the trial sponsor	<u>12</u>
	5c	Role of study sponsor and funders, if any, in study design; collection, management, and all signality and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	<u>12</u>
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee endpoint adjudication committee, data management team, and other individuals or groups over seeing the trial, if applicable (see Item 21a for data monitoring committee)	<u>NA</u>

Page	27	of	31	
------	----	----	----	--

Page	27 of 31		BMJ Open	
1 2	Introduction		02 22- 06	
3 4 5	Background and rationale	6a	Description of research question and justification for undertaking the trial, including sommary of relevant studies (published and unpublished) examining benefits and harms for each intervention	<u>3-4</u>
6 7		6b	Explanation for choice of comparators	<u>5</u>
8 9	Objectives	7	Specific objectives or hypotheses	<u>4</u>
10 11 12 13	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factoria single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	<u>4</u>
14 15	Methods: Participa	nts, int	erventions, and outcomes	
16 17 18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	<u>4-5</u>
19 20 21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	<u>6</u>
22 23 24 25	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	<u>6-7</u>
25 26 27 28		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	<u>6</u>
29 30 31		11c	Strategies to improve adherence to intervention protocols, and any procedures for meanitoring adherence (eg, drug tablet return, laboratory tests) \tilde{N}	<u>6</u>
32 33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	<u>6</u>
34 35 36 37 38 39	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable \vec{b} (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	<u>7-9</u>
40 41 42	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	<u>4,Table 1,Figure 1</u>
43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 28 of 31

			BMJ Open	
1 2	Sample size	14	Estimated number of participants needed to achieve study objectives and how it wasketermined, including clinical and statistical assumptions supporting any sample size calculationsໍ່ສູ່	
3 4 5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size $\frac{45}{9}$	<u>8-9</u>
6 7	Methods: Assignm	ent of i		
8 9	Allocation:		nterventions (for controlled trials)	<u>5</u>
10 11 12 13 14 15	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	<u>5</u>
16 17 18 19	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequent all y numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	<u>5</u>
20 21 22 23	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	<u>5</u>
24 25 26	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care proveders, outcome assessors, data analysts), and how	<u>5</u>
27 28 29		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	<u>5</u>
30 31 32	Methods: Data coll	ection,	management, and analysis	
32 33 34 35 36 37 38 39	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be four to the protocol	<u>9</u>
40 41 42 43 44 45		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	<u>9</u>

Page	29	of	31	
------	----	----	----	--

Page 29 of 31			BMJ Open	
1 2 3 4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>9-10</u>
4 5 6 7 8	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol \Box_{p}	<u>9-10</u>
8 9		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>9-19</u>
10 11 12 13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>9-10</u>
14 15	Methods: Monitorir	ng		
16 17 18 19 20 21	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternativels, an explanation of why a DMC is not needed	<u>9-10</u>
21 22 23 24		21b	Description of any interim analyses and stopping guidelines, including who will have because to these interim results and make the final decision to terminate the trial	<u>9-10</u>
25 26 27	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously geported adverse events and other unintended effects of trial interventions or trial conduct	<u>9-10</u>
27 28 29 30 31	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>9-10</u>
32 33	Ethics and dissemi	ination	2024 by g	
34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) apgroval	<u>5</u>
37 38 39 40 41 42 43	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility cutteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>NA</u>
44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

			BMJ Open			Р
1 2	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)		<u>6</u>	
3 4 5 6 7 8 9		26b	Additional consent provisions for collection and use of participant data and biological specin ancillary studies, if applicable	iens in	<u>6</u>	
	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, maintained in order to protect confidentiality before, during, and after the trial	and	<u>6</u>	
10 11 12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and ear study site	ch	<u>12</u>	
13 14 15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators		<u>6</u>	
16 17 18 19	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who for from trial participation	harm	<u>6</u>	
20 21 22 23	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions		<u>6</u>	
24 25		31b	Authorship eligibility guidelines and any intended use of professional writers		<u>6</u>	
26 27 28 29		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and sta code	tistical	<u>6</u>	
30 31	Appendices		3, 202			
32 33	Informed consent	32	Model consent form and other related documentation given to participants and authouts	<u>See</u>	e The	Ethics
34 35 36	materials		surrogates generation of the surrogates genet	App	proval Doc	<u>ument</u>
37 38 39	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for generative or molecular analysis in the current trial and for future use in ancillary studies, if application	r	<u>NA</u>	
40 41 42 43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml			

 mjopen-

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons an http://brinjopen.brinj.com/ on April 18. "Attribution-NonCommercial-NoDerivs 3.0 Unported" license. 42 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Acupuncture combined with cognitive-behavioral therapy for insomnia (CBT-I) in patients with insomnia: study protocol for a randomized controlled trial

L	
Journal:	BMJ Open
Manuscript ID	bmjopen-2022-063442.R2
Article Type:	Protocol
Date Submitted by the Author:	20-Nov-2022
Complete List of Authors:	Pei, Wenya; Sun Yat-sen University First Affiliated Hospital He, Te; South China University of Technology Yang, Pei; South China University of Technology Lv, Xiaozhou; Sun Yat-sen University First Affiliated Hospital Jiao, Boyu; Sun Yat-sen University First Affiliated Hospital Meng, Fanqi; Sun Yat-sen University First Affiliated Hospital Yan, Yingshuo; Sun Yat-sen University First Affiliated Hospital Cui, Liqian; Sun Yat-sen University First Affiliated Hospital He, Guanheng; Sun Yat-sen University First Affiliated Hospital Zhou, Xin; Sun Yat-sen University First Affiliated Hospital Wen, Guihua; South China University First Affiliated Hospital Wen, Jingwen; Sun Yat-sen University First Affiliated Hospital Lu, Liming; Guangzhou University of Chinese Medicine
Primary Subject Heading :	Complementary medicine
Secondary Subject Heading:	Health services research, Neurology, Public health
Keywords:	CLINICAL PHYSIOLOGY, Rehabilitation medicine < INTERNAL MEDICINE, COMPLEMENTARY MEDICINE, REHABILITATION MEDICINE

SCHOLARONE[™] Manuscripts

Acupuncture combined with cognitive-behavioral therapy for insomnia (CBT-I) in patients with insomnia: study protocol for a randomized controlled trial

Wenya Pei¹, Te He², Pei Yang², Xiaozhou Lv³, Boyu Jiao¹, Fanqi Meng¹, Yingshuo Yan⁴, Liqian Cui⁵, Guanheng He¹, Xin Zhou¹, Guihua Wen², Jingwen Ruan¹, Liming Lu⁶

¹Department of Acupuncture, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

² School of Computer Science and Engineering, South China University of Technology, Guangzhou, China

³Department of Traditional Chinese Medicine, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China

⁴Department of Respiratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

⁵Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China ⁶South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China.

Corresponding author:

Liming Lu. South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China. Email: lulimingleon@126.com

Jingwen Ruan. Department of Acupuncture, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Email: ruanjw@163.com

Guihua Wen. School of Computer Science and Engineering, South China University of

Technology, Guangzhou, China. Email: crghwen@scut.edu.cn

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Abstract

Introduction

Insomnia affects physical and mental health due to the lack of continuous and complete sleep architecture. Polysomnograms (PSGs) are used to record electrical information to perform sleep architecture using deep learning. Although acupuncture combined with cognitive-behavioral therapy for insomnia (CBT-I) could not only improve sleep quality, solve anxiety, depression but also ameliorate poor sleep habits and detrimental cognition. Therefore, this study will focus on the effects of electroacupuncture combined with CBT-I on sleep architecture with deep learning.

Methods and analysis

This randomized controlled trial will evaluate the efficacy and effectiveness of electroacupuncture combined with CBT-I in patients with insomnia. Participants will be randomized to receive either electroacupuncture combined with CBT-I or sham acupuncture combined with CBT-I and followed up for four weeks. The primary outcome is sleep quality, which is evaluated by the Pittsburgh sleep quality index(PSQI). The secondary outcome measures include a measurement of depression severity, anxiety, maladaptive cognitions associated with sleep, and adverse events. Sleep architecture will be assessed using deep learning on PSGs.

Ethics and dissemination

This trial has been approved by the institutional review boards and ethics committees of the First Affiliated Hospital of Sun Yat-sun University (2021763). The results will be disseminated through peer-reviewed journals. The results of this trial will be disseminated through peer-reviewed publications and conference abstracts or posters.

Trial registration number

CTR2100052502

Keywords: insomnia, cognitive behavioral therapy for insomnia, electroacupuncture, randomized controlled trial

BMJ Open

Strengths and limitations of this study

- This study will investigate the efficacy and effectiveness of electroacupuncture combined with CBT-I.
- We will observe the effects of electroacupuncture combined with CBT-I on sleep quality and sleep beliefs and attitudes of patients with insomnia.
- We will use deep learning to observe the effects of electroacupuncture combined with CBT-I on sleep architecture in different dimensions.
- The efficacy and effectiveness of electroacupuncture on sleep quality and sleep beliefs and attitudes of patients with insomnia will be further studied in the future.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Introduction

Insomnia is characterized by difficulties in initiating or maintaining sleep or impaired daytime functioning, which impact both physical and mental health^[1-3]. The lack of continuous and complete sleep architecture due to long-term fragmented and light sleep in patients with insomnia causes a decrease in sleep quality, which affects daily functions, and even induces anxiety, depression, and other mental symptoms^[4-6]. With the increasing pressures in daily life and work, insomnia is becoming a public health problem that needs to be solved urgently as it worsens the quality of life of patients, burdens caregivers, and increases social and economic costs^[7-9].

Cognitive-behavioral therapy for insomnia (CBT-I) is recommended as first-line treatment for insomnia and may improve sleep quality and alleviate poor sleep cognition in patients with insomnia^[10-12]. During the early stage of treatment, the sleep quality of patients with severe anxiety were improved slowly and the compliance of these patients were poor. Thus, as confirmed in previous studies, acupuncture combined with CBT-I could not only solve anxiety, depression, and other emotions caused by insomnia but also ameliorate poor sleep habits and detrimental cognition^[13-16].

However, there is a lack of rigorous clinical evidence on the treatment of insomnia with acupuncture combined with CBT-I; moreover, the clinical mechanism is unclear. In previous studies, we found that by analyzing polysomnograms (PSGs), electroacupuncture improves sleep architecture and prolongs the duration of slow-wave and rapid-eye-movement (REM) sleep^[17-19]. But whether acupuncture combined with CBT-I improves sleep architecture requires futher research.

During the past decade, the application of deep learning to automatic sleep staging using PSGs has shown promise for understanding the macrostructure of sleep. Deep learning allows the automatic extraction of features from data related to classification tasks, and the performance of deep neural networks continues to improve as the size of the dataset increases^[20-22].

Page 5 of 29

BMJ Open

Using a high-performance automatic sleep staging algorithm to analyze PSGs recordings via deep learning, this study will focus on the effects of electroacupuncture combined with CBT-I on sleep architecture, sleep quality, and sleep attitudes and beliefs in patients with insomnia. Furthermore, this research will provide guidance for electroacupuncture combined with CBT-I using artificial intelligence.

Methods

Study design

The study will be an assessor-blinded, randomized controlled trial. The protocol was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sun University (2021763). We will follow the Consolidated Standards of Reporting Trials and Standards for Reporting Interventions in Clinical Trials of Acupuncture guidelines for the design and reporting of the trial^[23, 24]. The flowchart of the trial is presented in Figure 1, and the schedule of enrolment, interventions, and outcome assessments are presented in Table 1.

Sample size calculations: Referring to the previous litetature^[25], we assume that the expected PSQI value of the observation group is 9.45 ± 1.84 and the control 6.43 ± 2.10 . We determine that a sample size of 11 per group would provide a power of 90% and an alpha level of 0.05, which would allow us to detect a difference in PSQI score between the two groups. Allowing for a 20% dropout rate, a sample size of 30 in each group is sufficient to meet statistical requirements.

Randomization, allocation, and blinding

Patients who are interested in participating in the trial will initially be screened by phone and then asked to participate in a face-to-face interview to conduct further surveys. After recruiting all participants, random numbers will be generated and assigned by a central randomization system of the Clinical Research and Data Center of Guangzhou University of Chinese Medicine. The researcher who will screen the eligible patients after baseline

BMJ	Open
-----	------

		BMJ Open			36/bmjopen-2022-063442 o	Pa
		Table 1 Re	esearch flow cha	rt	63442 or	
	Screening	Observation phase			Follow-upaphase	
Project	assession 0 pre-treament	Assession 1 pre-treament	Assession 2 Week 2±1day	Assession 3 Week 4±2day	Assessi&n 4 Week 8±22day	Unplanned follow-up
Medical history collection	\checkmark	-	-	-	¢r 2022.	
Sign the informed consent form	V	-	-	-	- D	
Inclusion criteria	V	-	-	-	ownle	
Exclusion criteria	\checkmark	0 -	-	-	- ec	
Basic Information	\checkmark	G.	-	-	d fron	
Vital signs	\checkmark	V		\checkmark	√ Ètt	*
Index of laboratory inspection	*	*	×	*	://bm	
PSG	-	\checkmark		\checkmark	- jopei	
Pittsburgh sleep quality index(PSQI)	-	\checkmark	V	\checkmark	√ n.bmj	
Beck depression inventory(BDI)	-	\checkmark	V	V	√ ^{So}	
Beck anxiety inventory(BAI)		\checkmark		V	√ ON	
DBAS-16	-	\checkmark		V	-√ ^A pril	
Adverse Events	-	*	*	*	×*	*
Medication records	-	\checkmark		\checkmark	Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by gu	
Terminate test evaluation	-	*	*	*	ية الق الق الق	

Notes: **"X**"Record when necessary; PSG: Long-term scalp electroencephalogram recording; DBAS-16: Dysfunctional Bellefs and Attitudes about Sleep Scale 16 versio

will assign patients to either the treatment or control group. Researchers, which include statisticians, outcome assessors, and data analysts, will all be blinded to patients' group assignments. Although acupuncturists will be not blinded to group assignment, they will not be involved in outcome assessments or data analyses. In addition, all researchers will undergo training for specific procedures before the trial begins.

Participants and recruitment

Patients will be recruited using hospital-based advertisements in the Department of Acupuncture and Department of Neurology of the First Affiliated Hospital of Sun Yat-sen University from January 2022 to December 2025.

The inclusion criteria will be as follows: (1) meets diagnostic criteria for insomnia based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition^[26] and the International Classification of Sleep Disorders, Third Edition^[27], (2) aged 18–65 years, (3) experienced insomnia for more than 1 month but less than 2 years before the start of the trial, (4) voluntarily agrees to participate in the investigation and provides written informed consent before the clinical trial starts.

The exclusion criteria will be as follows: (1) serious cardiovascular, liver, kidney, or hematopoietic system disease, (2) insomnia was caused by a nervous system disease (e.g., stroke or Parkinson's disease), (3) insomnia was caused by a mental disorder, such as depression or anxiety, (4) history of sleep apnea, (5) pregnant or lactating women, (6) have received or currently receiving CBT-I.

Withdrawal criteria will be as follows: (1) patient withdrawal from the trial because of personal reasons, (2) patient has an adverse reaction related to acupuncture and refuses to continue treatment, (3) during the follow-up period, the patient cannot be contacted because of change of address and telephone number.

Intervention

The intervention will begin the day following randomization. All participants will receive 20 times treatments (five times per week for 4 weeks).

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Observation group

Acupuncture treatment

Patients' skin will be disinfected with 75% alcohol, and patients will be asked to lie supine and wear eye masks for a better curative effect. Each participant will receive acupuncture treatment from the same acupuncturist who has more than 5 years of clinical experience in acupuncture therapy. The temperature of the treatment room will not be lower than 25°C.

Patients in the acupuncture group will receive electroacupuncture treatment on Sishenchong (EX-HN1), bilateral Neiguan (PC6), bilateral Taixi (KI3), bilateral Shenmen (HT7), and bilateral Sanyinjiao (SP6)^[28]. Tube-guided acupuncture needles will be inserted to a depth of 17-25 mm at each acupoint (acupuncture location and method for each acupoint are provided in Table 2 and Figure 2). A low-frequency electronic pulse therapy instrument (G6805-2A, Shanghai Huayi Medical Instrument Co., Shanghai, China) will be used with 10-Hz continuous waves, and the current will range from 1 to 5 mA which will be adjusted based on the tolerance of each patient.

CBT-I treatment

CBT-I will be given while acupuncture treatment is in progress. The intervention will consist of behavioral components (e.g. sleep restriction and stimulus control), cognitive components (e.g., cognitive restructuring and paradoxical intention), progressive muscle relaxation, and sleep hygiene^[29].

Control group

The procedure for the control group will be the same as that for the observation group with no CBT-I treatment. The major difference in interventions between the two groups being the tube needling method, in which no needle will be inserted through the tube for patients in the control group. To mimic the sensation of a real needle being inserted into the body, the acupuncturist will place the tube close to the skin at the acupoint and tap the top of the tube.

Quality control

The trial will be conducted under the supervision of the First Affiliated Hospital of Sun Yat-sun University. A qualified clinical trial expert will be invited to monitor the study to identify problems during the trial, examine collected data, and control bias.

Outcome measures

Primary outcome

Pittsburgh sleep quality index

The Pittsburgh sleep quality index (PSQI) is an internationally established tool that is used to evaluate sleep quality. The scale includes seven dimensions that consist of subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, sleeping medication, and daytime dysfunction. The score correlates adversely with sleep quality which a higher score means the sleep quality is worse, and each factor has a score of 0 to 3 to provide a total score of 21 points^[30, 31].

Secondary outcomes

The Beck depression inventory

The Beck depression inventory (BDI) is a valid self-assessment index to measure depression severity and consists of 13 items. Each item is scored from 0 to 3 (0 to 4 indicates no depression, 5 to 7 indicates mild depression, 8 to 15 indicates moderate depression), with a score of 16 points or more considered as severe depression^{[32-34].}

The Beck anxiety inventory

The Beck anxiety inventory (BAI) is used to assess the degree of anxiety and consists of 21 items scored from 1 to 4 (15 to 25 points indicates mild anxiety, 26 to 35 points indicates moderate anxiety, and 36 points is considered severe anxiety)^[35, 36].

The Dysfunctional Beliefs and Attitudes about Sleep Scale 16 version

The Dysfunctional Beliefs and Attitudes about Sleep Scale 16 version (DBAS-16) is used to evaluate maladaptive cognitions associated with sleep. There are 16 items in the index, which are divided into four factors comprising consequences of insomnia, worry about

	BMJ Open	acupoint 36/bmjopen-2022-063442 Needling method
	Table 2 Acupuncture location and method for each	acupoint 9 30 Dec
Acupoint	Location	Needling method
Sishenchong (EX-HN1)	On the parietal region, 1 cun anterior ,posterior and lateral to Baihui, 4 acpoints totally.	The angle between the needle tip and the scalp is 30_{\circ} . Nove the needle tip backward along the anterioreposterior midline, and then meetle 0.5 cun.
Neiguan(PC6)	On the line joining Daling and Quze, between the tendons of palmaris longus and flexor carpi radialis, 2 cun above the transverse crease of the wrist.	Puncture perpendicularly 1-1.5 cun.
Taixi (KI3)	In the depression between the tip of the medial malleolus and the Achilles tendon.	Puncture perpendicalarly 0.5-1 cun.
Shenmen (HT7)	On the palmar ulnar end of the transverse crease of the wrist, and on the radial aspect of the tendon of the ulnar flexor m. of the wrist.	Puncture perpendicularly 0.5-1 cun.
Sanyinjiao (SP6)	Posterior to the mesial border of the tibia, and 3 cun above the tip of the medial malleolus	<u> </u>
	For peer review only - http://bmjopen.bmj.com/site/about/gui	18, 2024 by guest. Protected by copyright.

BMJ Open

sleep, sleep expectations, and medication. These factors are scored on a scale of 1-5(strongly disagree to strongly agree). The total score is positively correlated with the reasonableness of sleep beliefs and attitudes^[37, 38].

Sleep staging

The PARADISEP&D9600 (U.S.) Polysomnography Monitoring and Analysis System will be used to simultaneously monitor EEG, EOG, and EMG. A large clinical dataset of PSG recordings will be used to train a hybrid convolutional neural network (CNN) and recurrent neural network (RNN) to learn effective and generalizable features for sleep stage scoring^[39, 40]. Then clinical data will be used to indentify the deep learning algorithm. Sleep staging for both datasets will be performed by expert sleep technicians in nonoverlapping 30-s epochs according to standards by the American Academy of Sleep Medicine(AASM), as one of five stages: wake(W), non-rapid eye movement(REM) stage 1(N1), non-REM stage 2(N2), non-REM stage 3(N3), and rapid eye movement (REM)^[41].

Adverse events

During treatment and four week after treatment, a questionnaire will be administered to evaluate the various discomforts that may be caused by acupuncture: hangover, addiction, tolerance, fatigue after waking, insomnia rebound, daytime alertness, cognitive function, and behavior ability.

Patients and public involvement

Patients and the public are not involved in the design or conduct of the study or the outcome measures, and no attempt will be made to assess the burden of the intervention on the patients themselves. The results of this study will be disseminated to study participants via the website of our hospitals.

Statistical analysis

All analyses will be performed on the intention-to-treat population of participants who had at least one treatment. Missing data will be replaced according to the principle of the

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

last observation carried forward. Data analyses will be performed using the SPSS version 25 (IBM Corp.) software. All available data will be analyzed descriptively. For continuous data, the normality test will be applied at the beginning of the analysis.
Results will be presented as means, standard deviations, and 95% confidence intervals (CIs) for continuous data that conform to the normal distribution and medians, quartiles, and ranges for rank data and continuous data that are not normally distributed. Discrete data will be presented as percentages.
We will first examine the descriptive data for sample characteristics at baseline, and independent samples t-tests will be used to compare groups for continuous variables,

independent samples t-tests will be used to compare groups for continuous variables, whereas chi-square analysis will be used to compare groups for dichotomous variables. Second, we will perform two series of repeated-measures and univariate analyses of covariance (ANCOVA) models to examine treatment effects. We will use repeated-measures ANCOVAs to analyze the primary and secondary outcome measures (i.e., PSQI, BDI, BAI, DBAS-16, and sleep staging scores) from pre-treatment to post-treatment. If a significant effect is observed, we will conduct posthoc paired samples t-tests to examine within-group changes in study outcomes. For all study outcomes, we will then perform univariate ANCOVAs to test for group differences in post-treatment values while controlling for relevant covariates. This process will be repeated to examine changes in study outcomes from pretreatment to postnatal follow-up.

When necessary, ITT analysis and sensitivity analysis will be used to assess the robustness of the conclusions of the entire clinical trial. To evaluate the consistency of the trial and explore the factors that affect efficacy or prognosis, subgroup analysis will be conducted to identify the population with better efficacy. Safety analysis will be used to assess the incidence of adverse events and related symptoms in patients with insomnia during treatment and follow-up.

Limitations

Currently, CBT-I is recommended as a first-line treatment for insomnia, but it is limited in clinical practice especially in developing countries such as China^[42-45]. As a complementary alternative therapy with a long history in China, acupuncture has been used as a clinical treatment for insomnia with fewer adverse effects and less permanent damage in previous studies^[13, 14, 16]. In this study, we will focus on whether electroacupuncture combined with CBT-I could influence sleep quality and sleep architecture, but whether acupuncture therapy alone could influence sleep habits and correct cognition, also sleep architecture worth futher research.

During the past decade, there have been various advances in automated sleep staging of PSGs data using the ability of deep learning methods to automatically extract features from data that are relevant to the classification, moreover, the performance of deep neural networks continues to improve as datasets become larger^[46-50]. To analyze the effects of electroacupuncture combined with CBT-I on sleep architecture, deep learning will be used to analyze PSGs in various clinical settings in this study. But due to lack of acceptability among patients, some of the participants received placebo treatment will drop, which may make analyses no meaningful due to the small number of participants in each arm. Notwithstanding, we will be able to optimize the randomized design and statistical analysis to avoid systematic errors and minimize the bias.

Acknowledgments

Not applicable.

Footnotes

Contributors: Wenya Pei and Te He designed the trial protocol and drafted the manuscript. Liming Lu, Jingwen Ruan, and Guihua Wen revised the manuscript. Pei Yang, Xiaozhou Lv, and Boyu Jiao will plan the data analysis. Liqian Cui, Yingshuo Yan, Fanqi Meng,

Guanheng He, and Xin Zhou will participate in participant recruitment. All authors discussed, read, and revised the manuscript, and all approved the publication of this protocol.

Funding: The study was supported by the Key R&D Program of Guangdong Province (2020B1111120001).

Competing interests: None declared.

Patient consent for publication: Not applicable

Provenance and peer review: Not commissioned; externally peer-reviewed.

Ethics statements

Patient consent for publication

Not applicable.

Ethics approval and consent to participate: The study was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sun University (2021763). Participants will be included only after they provide written informed consent. The study was registered in the Chinese Clinical Trial Registry (No.ChiCTR2100052502,

30/10/2021).

References

1. Riemann D, Benz F, Dressle RJ, Espie CA, Johann AF, Blanken TF, Leerssen J, Wassing R, Henry AL, Kyle SD et al: Insomnia disorder: State of the science and challenges for the future. Journal of sleep research 2022, 31(4):e13604.

2. Chan WS, Levsen MP, McCrae CS: A meta-analysis of associations between obesity and insomnia diagnosis and symptoms. Sleep medicine reviews 2018, 40:170-182.

3. Wickwire EM: The Value of Digital Insomnia Therapeutics: What We Know and What We Need To Know. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2019, 15(1):11-13.

4. Kalmbach DA, Anderson JR, Drake CL: The impact of stress on sleep: Pathogenic sleep reactivity as a vulnerability to insomnia and circadian disorders. Journal of sleep research 2018, 27(6):e12710.

5. Shekleton JA, Flynn-Evans EE, Miller B, Epstein LJ, Kirsch D, Brogna LA, Burke LM, Bremer E, Murray JM, Gehrman P et al: Neurobehavioral performance impairment in insomnia: relationships with self-reported sleep and daytime functioning. Sleep 2014, 37(1):107-116.

Cross NE, Carrier J, Postuma RB, Gosselin N, Kakinami L, Thompson C, Chouchou F, Dang-Vu TT: Association between insomnia disorder and cognitive function in middle-aged and older adults: a cross-sectional analysis of the Canadian Longitudinal Study on Aging. Sleep 2019, 42(8).

7. Singareddy R, Vgontzas AN, Fernandez-Mendoza J, Liao D, Calhoun S, Shaffer ML, Bixler EO: Risk factors for incident chronic insomnia: a general population prospective study. Sleep medicine 2012, 13(4):346-353.

8. Zhang Y, Ren R, Lei F, Zhou J, Zhang J, Wing YK, Sanford LD, Tang X: Worldwide and regional prevalence rates of co-occurrence of insomnia and insomnia symptoms with obstructive sleep apnea: A systematic review and meta-analysis. Sleep medicine reviews 2019, 45:1-17.

9. Kessler RC, Berglund PA, Coulouvrat C, Fitzgerald T, Hajak G, Roth T, Shahly V, Shillington AC, Stephenson JJ, Walsh JK: Insomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia Survey. Sleep 2012, 35(6):825-834.

Kalmbach DA, Cheng P, Arnedt JT, Cuamatzi-Castelan A, Atkinson RL,
 Fellman-Couture C, Roehrs T, Drake CL: Improving Daytime Functioning, Work
 Performance, and Quality of Life in Postmenopausal Women With Insomnia: Comparing
 Cognitive Behavioral Therapy for Insomnia, Sleep Restriction Therapy, and Sleep

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Hygiene Education. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2019, 15(7):999-1010.

 Espie CA, Emsley R, Kyle SD, Gordon C, Drake CL, Siriwardena AN, Cape J, Ong JC, Sheaves B, Foster R et al: Effect of Digital Cognitive Behavioral Therapy for Insomnia on Health, Psychological Well-being, and Sleep-Related Quality of Life: A Randomized Clinical Trial. JAMA psychiatry 2019, 76(1):21-30.

 Thakral M, Von Korff M, McCurry SM, Morin CM, Vitiello MV: Changes in dysfunctional beliefs about sleep after cognitive behavioral therapy for insomnia: A systematic literature review and meta-analysis. Sleep medicine reviews 2020, 49:101230.
 Garland SN, Xie SX, DuHamel K, Bao T, Li Q, Barg FK, Song S, Kantoff P, Gehrman P, Mao JJ: Acupuncture Versus Cognitive Behavioral Therapy for Insomnia in Cancer Survivors: A Randomized Clinical Trial. Journal of the National Cancer Institute 2019, 111(12):1323-1331.

14. Liou KT, Root JC, Garland SN, Green J, Li Y, Li QS, Kantoff PW, Ahles TA, Mao JJ: Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial. Cancer 2020, 126(13):3042-3052.

15. Xing J, Wu X, Liu H, Wang J, Jiang S, Lozada A, Wang Y: Effects ofElectroacupuncture Therapy and Cognitive Behavioral Therapy in Chronic Insomnia: ARandomized Controlled Study. Evidence-based complementary and alternative medicine :eCAM 2020, 2020:5630130.

16. Cui L, Jingwen R, Minying Z, Guanheng H, Hao L: Effects of acupuncture combined with cognitive behavioral therapy on sleep quality, sleep belief and attitude in patients with chronic insomnia. Guangdong Medical Journal 2020, 41(10):1005-1009.

Ruan JW, Wang CH, Liao XX, Yan YS, Hu YH, Rao ZD, Wen M, Zeng XX, Lai XX: Electroacupuncture treatment of chronic insomniacs. Chin Med J (Engl) 2009, 122(23):2869-2873.

4 5

6 7

8 9

10 11

12 13

14 15

16 17

18 19

20 21

22 23

24 25

26 27

28

29

30 31

32

33 34

35 36

37 38

39 40

41 42

43 44

45 46

47 48

49 50

51 52

60

BMJ Open

18. Yin X, Gou M, Xu J, Dong B, Yin P, Masquelin F, Wu J, Lao L, Xu S: Efficacy and
safety of acupuncture treatment on primary insomnia: a randomized controlled trial.
Sleep medicine 2017, 37:193-200.
19. Pei W, Peng R, Gu Y, Zhou X, Ruan J: Research trends of acupuncture therapy on
insomnia in two decades (from 1999 to 2018):a bibliometric analysis. BMC
complementary and alternative medicine 2019, 19(1):225.
20. Gorban AN, Makarov VA, Tyukin IY: The unreasonable effectiveness of small
neural ensembles in high-dimensional brain. Physics of life reviews 2019, 29:55-88.
21. Bresch E, Großekathöfer U, Garcia-Molina G: Recurrent Deep Neural Networks for
Real-Time Sleep Stage Classification From Single Channel EEG. Frontiers in
computational neuroscience 2018, 12:85.
22. Hassan AR, Bhuiyan MIH: Automated identification of sleep states from EEG
signals by means of ensemble empirical mode decomposition and random under sampling
boosting. Computer methods and programs in biomedicine 2017, 140:201-210.
23. Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: updated guidelines
for reporting parallel group randomised trials. BMJ (Clinical research ed) 2010,
340:c332.
24. MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A,
Moher D: Revised STandards for Reporting Interventions in Clinical Trials of
Acupuncture (STRICTA): Extending the CONSORT statement. Journal of
evidence-based medicine 2010, 3(3):140-155.
25. Wang C, Yang WJ, Yu XT, Fu C, Li JJ, Wang J, Xu WL, Zheng YX, Chen XY,
Chen YF: Acupuncture for insomnia with short sleep duration: protocol for a randomised
controlled trial. BMJ open 2020, 10(3):e033731.
26. Battle DE: Diagnostic and Statistical Manual of Mental Disorders (DSM). CoDAS
2013, 25(2):191-192.
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

27. Sateia MJ: International classification of sleep disorders-third edition: highlights and modifications. Chest 2014, 146(5):1387-1394.

28. Cui, L, Ruan, J, Zheng, M, He, G, Li H: Effects of acupuncture combined with cognitive behavioral therapy on sleep quality, sleep belief and attitude in patients with chronic insomnia. Guangdong Medical Journal 2020, 41(10):1005-1009.

29. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD: Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Annals of internal medicine 2016, 165(2):125-133.

30. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry research 1989, 28(2):193-213.

31. Mollayeva T, Thurairajah P, Burton K, Mollayeva S, Shapiro CM, Colantonio A: The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and meta-analysis. Sleep medicine reviews 2016, 25:52-73.

32. Robinson BE, Kelley L: Concurrent validity of the Beck Depression Inventory as a measure of depression. Psychological reports 1996, 79(3 Pt 1):929-930.

33. Piotrowski C: Use of the Beck Depression Inventory in clinical practice.Psychological reports 1996, 79(3 Pt 1):873-874.

34. Carney CE, Ulmer C, Edinger JD, Krystal AD, Knauss F: Assessing depression symptoms in those with insomnia: an examination of the beck depression inventory second edition (BDI-II). Journal of psychiatric research 2009, 43(5):576-582.

35. Beck AT, Epstein N, Brown G, Steer RA: An inventory for measuring clinical anxiety: psychometric properties. Journal of consulting and clinical psychology 1988, 56(6):893-897.

36. Nyer M, Farabaugh A, Fehling K, Soskin D, Holt D, Papakostas GI, Pedrelli P, FavaM, Pisoni A, Vitolo O et al: Relationship between sleep disturbance and depression,

1	
2	
3	
4	
5	
6	
6 7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
16 17	
10	
18	
19	
20	
21 22	
22	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

anxiety, and functioning in college students. Depression and anxiety 2013, 30(9):873-880. 37. Morin CM, Vallières A, Ivers H: Dysfunctional beliefs and attitudes about sleep (DBAS): validation of a brief version (DBAS-16). Sleep 2007, 30(11):1547-1554. 38. Chung KF, Ho FY, Yeung WF: Psychometric Comparison of the Full and Abbreviated Versions of the Dysfunctional Beliefs and Attitudes about Sleep Scale. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2016, 12(6):821-828. 39. Ramaswamy SM, Weerink MAS, Struys M, Nagaraj SB: Dexmedetomidine-induced deep sedation mimics non-rapid eye movement stage 3 sleep: large-scale validation using machine learning. Sleep 2021, 44(2). 40. Abou Jaoude M, Sun H, Pellerin KR, Pavlova M, Sarkis RA, Cash SS, Westover MB, Lam AD: Expert-level automated sleep staging of long-term scalp electroencephalography recordings using deep learning. Sleep 2020, 43(11). 41. Malhotra RK, Kirsch DB, Kristo DA, Olson EJ, Aurora RN, Carden KA, Chervin RD, Martin JL, Ramar K, Rosen CL et al: Polysomnography for Obstructive Sleep Apnea Should Include Arousal-Based Scoring: An American Academy of Sleep Medicine Position Statement. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2018, 14(7):1245-1247. 42. Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, Espie CA, Garcia-Borreguero D, Gjerstad M, Gonçalves M et al: European guideline for the diagnosis and treatment of insomnia. Journal of sleep research 2017, 26(6):675-700. 43. Kathol RG, Arnedt JT: Cognitive Behavioral Therapy for Chronic Insomnia: Confronting the Challenges to Implementation. Annals of internal medicine 2016, 165(2):149-150.

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

44. Ree M, Junge M, Cunnington D: Australasian Sleep Association position statement regarding the use of psychological/behavioral treatments in the management of insomnia in adults. Sleep medicine 2017, 36 Suppl 1:S43-s47.

45. Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ, Lichstein KL, Sateia MJ, Troxel WM, Zhou ES, Kazmi U et al: Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2021, 17(2):255-262.

46. Zhang L, Fabbri D, Upender R, Kent D: Automated sleep stage scoring of the Sleep Heart Health Study using deep neural networks. Sleep 2019, 42(11).

47. Feige B, Baumgartner B, Meyer D, Riemann D: The Relationship Between PSG and Morning/Evening Emotional Parameters in Patients With Insomnia Disorder and Good Sleepers. Frontiers in psychology 2018, 9:2712.


Lajnef T, Chaibi S, Ruby P, Aguera PE, Eichenlaub JB, Samet M, Kachouri A, Jerbi K: Learning machines and sleeping brains: Automatic sleep stage classification using decision-tree multi-class support vector machines. Journal of neuroscience methods 2015, 250:94-105.


49. Qu W, Wang Z, Hong H, Chi Z, Feng DD, Grunstein R, Gordon C: A Residual Based Attention Model for EEG Based Sleep Staging. IEEE journal of biomedical and health informatics 2020, 24(10):2833-2843.

50. Wang Y, Loparo KA, Kelly MR, Kaplan RF: Evaluation of an automated single-channel sleep staging algorithm. Nature and science of sleep 2015, 7:101-111.

rage 21 01 29	
$ 1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \\ 22 \\ 23 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 29 \\ 30 \\ 31 \\ 32 \\ 33 \\ 34 \\ 35 \\ 36 \\ 37 \\ 38 \\ 39 \\ 40 \\ 41 \\ 42 \\ 43 \\ 44 \\ 45 \\ 46 \\ 47 \\ 48 \\ 49 \\ 50 \\ 51 \\ 52 \\ 53 \\ 54 \\ 55 \\ 56 \\ 57 \\ 58 \\ 59 $	Fig 1. CONSORT 2010 Flow Diagram Fig 2. Location of acupoints
60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright.





33 34

		BMJ Open g	
		BMJ Open SPRICE Standard Protocol Items: Recommendations for Interventional Trials	
SPIRIT 2013 Check Section/item	list: Reco Item No	Description Desc	Addressed on page number
Administrative info	ormatior	n Downlog	
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicate, trial acronym	<u>1</u>
Trial registration	2a		<u>1</u>
	2b	Trial identifier and registry name. If not yet registered, name of intended registry All items from the World Health Organization Trial Registration Data Set	<u>1</u>
Protocol version	3	Date and version identifier	<u>1</u>
Funding	4	Sources and types of financial, material, and other support	<u>12</u>
Roles and	5a	Names, affiliations, and roles of protocol contributors	<u>1,12</u>
responsibilities	5b	Name and contact information for the trial sponsor	<u>12</u>
	5c	Role of study sponsor and funders, if any, in study design; collection, management, a all all sis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	<u>12</u>
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups over seeing the trial, if applicable (see Item 21a for data monitoring committee)	<u>NA</u>

Page	25	of	29
------	----	----	----

Page	25 of 29		BMJ Open	
1 2	Introduction		2022-06	
2 3 4 5 6 7	Background and rationale	6a	مع Description of research question and justification for undertaking the trial, including semmary of relevant studies (published and unpublished) examining benefits and harms for each	<u>3-4</u>
		6b	Explanation for choice of comparators $\begin{tabular}{c} & & & & & \\ & & & & & & \\ & & & & & & $	<u>5</u>
8 9	Objectives	7	Specific objectives or hypotheses	<u>4</u>
10 11 12 13	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factoria single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	<u>4</u>
14 15	Methods: Participa	nts, int	erventions, and outcomes	
16 17 18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	<u>4-5</u>
19 20 21 22 23 24	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	<u>6</u>
	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	<u>6-7</u>
25 26 27 28		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	<u>6</u>
29 30 31		11c	Strategies to improve adherence to intervention protocols, and any procedures for menitoring adherence (eg, drug tablet return, laboratory tests)	<u>6</u>
32 33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	<u>6</u>
34 35 36 37 38 39 40 41 42	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	<u>7-9</u>
	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	4,Table 1,Figure 1
43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 26 of 29

			BMJ Open	
1 2 3	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculationsໍ່ສູ່	
3 4 5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size $\frac{1}{2}$	<u>8-9</u>
6 7	Methods: Assignm	ent of i	nterventions (for controlled trials)	
8 9	Allocation:			<u>5</u>
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is up available to those who enrol participants or assign interventions	<u>5</u>
	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	<u>5</u>
	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	<u>5</u>
	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care proveeers, outcome assessors, data analysts), and how	<u>5</u>
27 28 29		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	<u>5</u>
30 31 32 33 34 35 36 37 38 39	Methods: Data coll	ection,	management, and analysis	
	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be four d, if not in the protocol	<u>9</u>
40 41 42 43 44 45		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	<u>9</u>

Page	27	of	29
------	----	----	----

Page 27 of 29			BMJ Open	
1 2 3 4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>9-10</u>
5 6 7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>9-10</u>
8 9		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>9-19</u>
10 11 12 13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>9-10</u>
14 15	Methods: Monitorir	ng	n load	
16 17 18 19 20	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>9-10</u>
21 22 23 24		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>9-10</u>
25 26 27	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously eported adverse events and other unintended effects of trial interventions or trial conduct	<u>9-10</u>
28 29 30 31	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>9-10</u>
32	Ethics and dissemi	ination	2024 by g	
33 34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) ap ਸ਼੍ਰਾ	<u>5</u>
37 38 39 40 41 42 43	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility cetteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>NA</u>
44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

46

			BMJ Open	mjopen			Р
1 2	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authori surrogates, and how (see Item 32)	-20 % -0632		<u>6</u>	
3 4 5 6		26b	Additional consent provisions for collection and use of participant data and biological ancillary studies, if applicable	¹⁴ Specimens in S		<u>6</u>	
6 7 8 9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, maintained in order to protect confidentiality before, during, and after the trial	ପ୍ରକାର Shared, and		<u>6</u>	
10 11 12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial study site	and each		<u>12</u>	
13 14 15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contrac agreements that limit such access for investigators	ow Bijal Doadeo		<u>6</u>	
16 17 18 19	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who from trial participation	a suffer harm		<u>6</u>	
20 21 22 23	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healt professionals, the public, and other relevant groups (eg, via publication, reporting in databases, or other data sharing arrangements), including any publication restriction	sults		<u>6</u>	
24 25		31b	Authorship eligibility guidelines and any intended use of professional writers	mj.co		<u>6</u>	
26 27 28 29		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, code	agnd statistical April 18		<u>6</u>	
30 31	Appendices			3, 202			
32 33	Informed consent	32	Model consent form and other related documentation given to participants and author	uesed	See	The	Ethics
34 35 36 37 38 39	materials		surrogates	juest. Prof	<u>Approv</u>	val Doc	<u>ument</u>
	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for gemolecular analysis in the current trial and for future use in ancillary studies, if application	etic or		<u>NA</u>	
40 41 42 43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	copyright.			

 mjopen-

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons an http://brinjopen.brinj.com/ on April 18. "Attribution-NonCommercial-NoDerivs 3.0 Unported" license. 42 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Acupuncture combined with cognitive-behavioral therapy for insomnia (CBT-I) in patients with insomnia: study protocol for a randomized controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-063442.R3
Article Type:	Protocol
Date Submitted by the Author:	08-Dec-2022
Complete List of Authors:	Pei, Wenya; Sun Yat-sen University First Affiliated Hospital He, Te; South China University of Technology Yang, Pei; South China University of Technology Lv, Xiaozhou; Sun Yat-sen University First Affiliated Hospital Jiao, Boyu; Sun Yat-sen University First Affiliated Hospital Meng, Fanqi; Sun Yat-sen University First Affiliated Hospital Yan, Yingshuo; Sun Yat-sen University First Affiliated Hospital Cui, Liqian; Sun Yat-sen University First Affiliated Hospital He, Guanheng; Sun Yat-sen University First Affiliated Hospital Zhou, Xin; Sun Yat-sen University First Affiliated Hospital Wen, Guihua; South China University First Affiliated Hospital Wen, Jingwen; Sun Yat-sen University First Affiliated Hospital Lu, Liming; Guangzhou University of Chinese Medicine
Primary Subject Heading :	Complementary medicine
Secondary Subject Heading:	Health services research, Neurology, Public health
Keywords:	CLINICAL PHYSIOLOGY, Rehabilitation medicine < INTERNAL MEDICINE, COMPLEMENTARY MEDICINE, REHABILITATION MEDICINE

SCHOLARONE[™] Manuscripts

Acupuncture combined with cognitive-behavioral therapy for insomnia (CBT-I) in patients with insomnia: study protocol for a randomized controlled trial

Wenya Pei¹, Te He², Pei Yang², Xiaozhou Lv³, Boyu Jiao¹, Fanqi Meng¹, Yingshuo Yan⁴, Liqian Cui⁵, Guanheng He¹, Xin Zhou¹, Guihua Wen², Jingwen Ruan¹, Liming Lu⁶

¹Department of Acupuncture, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

² School of Computer Science and Engineering, South China University of Technology, Guangzhou, China

³Department of Traditional Chinese Medicine, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China

⁴Department of Respiratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

⁵Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China ⁶South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China.

Corresponding author:

Liming Lu. South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China. Email: lulimingleon@126.com

Jingwen Ruan. Department of Acupuncture, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Email: ruanjw@163.com

Guihua Wen. School of Computer Science and Engineering, South China University of

Technology, Guangzhou, China. Email: crghwen@scut.edu.cn

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Abstract

Introduction

Insomnia affects physical and mental health due to the lack of continuous and complete sleep architecture. Polysomnograms (PSGs) are used to record electrical information to perform sleep architecture using deep learning. Although acupuncture combined with cognitive-behavioral therapy for insomnia (CBT-I) could not only improve sleep quality, solve anxiety, depression but also ameliorate poor sleep habits and detrimental cognition. Therefore, this study will focus on the effects of electroacupuncture combined with CBT-I on sleep architecture with deep learning.

Methods and analysis

This randomized controlled trial will evaluate the efficacy and effectiveness of electroacupuncture combined with CBT-I in patients with insomnia. Participants will be randomized to receive either electroacupuncture combined with CBT-I or sham acupuncture combined with CBT-I and followed up for four weeks. The primary outcome is sleep quality, which is evaluated by the Pittsburgh sleep quality index(PSQI). The secondary outcome measures include a measurement of depression severity, anxiety, maladaptive cognitions associated with sleep, and adverse events. Sleep architecture will be assessed using deep learning on PSGs.

Ethics and dissemination

This trial has been approved by the institutional review boards and ethics committees of the First Affiliated Hospital of Sun Yat-sun University (2021763). The results will be disseminated through peer-reviewed journals. The results of this trial will be disseminated through peer-reviewed publications and conference abstracts or posters.

Trial registration number

CTR2100052502

Keywords: insomnia, cognitive behavioral therapy for insomnia, electroacupuncture, randomized controlled trial

BMJ Open

Strengths and limitations of this study

- This study will investigate the efficacy and effectiveness of electroacupuncture combined with CBT-I.
- We will use deep learning to observe the effects of electroacupuncture combined with CBT-I on sleep architecture in different dimensions.
- The efficacy and effectiveness of electroacupuncture on sleep quality and sleep beliefs and attitudes of patients with insomnia will be further studied in the future.
- Although we explained the randomized design and statistical analysis through ITT analysis and sensitivity analysis to some extent, systematic errors and bias remained uncertain.

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Introduction

Insomnia is characterized by difficulties in initiating or maintaining sleep or impaired daytime functioning, which impact both physical and mental health^[1-3]. The lack of continuous and complete sleep architecture due to long-term fragmented and light sleep in patients with insomnia causes a decrease in sleep quality, which affects daily functions, and even induces anxiety, depression, and other mental symptoms^[4-6]. With the increasing pressures in daily life and work, insomnia is becoming a public health problem that needs to be solved urgently as it worsens the quality of life of patients, burdens caregivers, and increases social and economic costs^[7-9].

Cognitive-behavioral therapy for insomnia (CBT-I) is recommended as first-line treatment for insomnia and may improve sleep quality and alleviate poor sleep cognition in patients with insomnia^[10-12]. During the early stage of treatment, the sleep quality of patients with severe anxiety were improved slowly and the compliance of these patients were poor. Thus, as confirmed in previous studies, acupuncture combined with CBT-I could not only solve anxiety, depression, and other emotions caused by insomnia but also ameliorate poor sleep habits and detrimental cognition^[13-16].

However, there is a lack of rigorous clinical evidence on the treatment of insomnia with acupuncture combined with CBT-I; moreover, the clinical mechanism is unclear. In previous studies, we found that by analyzing polysomnograms (PSGs), electroacupuncture improves sleep architecture and prolongs the duration of slow-wave and rapid-eye-movement (REM) sleep^[17-19]. But whether acupuncture combined with CBT-I improves sleep architecture requires futher research.

During the past decade, the application of deep learning to automatic sleep staging using PSGs has shown promise for understanding the macrostructure of sleep. Deep learning allows the automatic extraction of features from data related to classification tasks, and the performance of deep neural networks continues to improve as the size of the dataset increases^[20-22].

Page 5 of 29

BMJ Open

Using a high-performance automatic sleep staging algorithm to analyze PSGs recordings via deep learning, this study will focus on the effects of electroacupuncture combined with CBT-I on sleep architecture, sleep quality, and sleep attitudes and beliefs in patients with insomnia. Furthermore, this research will provide guidance for electroacupuncture combined with CBT-I using artificial intelligence.

Methods

Study design

The study will be an assessor-blinded, randomized controlled trial. The protocol was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sun University (2021763). We will follow the Consolidated Standards of Reporting Trials and Standards for Reporting Interventions in Clinical Trials of Acupuncture guidelines for the design and reporting of the trial^[23, 24]. The flowchart of the trial is presented in Figure 1, and the schedule of enrolment, interventions, and outcome assessments are presented in Table 1.

Sample size calculations: Referring to the previous litetature^[25], we assume that the expected PSQI value of the observation group is 9.45 ± 1.84 and the control 6.43 ± 2.10 . We determine that a sample size of 11 per group would provide a power of 90% and an alpha level of 0.05, which would allow us to detect a difference in PSQI score between the two groups. Allowing for a 20% dropout rate, a sample size of 30 in each group is sufficient to meet statistical requirements.

Randomization, allocation, and blinding

Patients who are interested in participating in the trial will initially be screened by phone and then asked to participate in a face-to-face interview to conduct further surveys. After recruiting all participants, random numbers will be generated and assigned by a central randomization system of the Clinical Research and Data Center of Guangzhou University of Chinese Medicine. The researcher who will screen the eligible patients after baseline

BMJ	Open
-----	------

	BMJ Open				36/bmjopen-2022-063442 o	Pa
		Table 1 Re	esearch flow cha	rt	63442 or	
	Screening	Observation phase			Follow-upaphase	
Project	assession 0 pre-treament	Assession 1 pre-treament	Assession 2 Week 2±1day	Assession 3 Week 4±2day	Assessi&n 4 Week 8±22day	Unplanned follow-up
Medical history collection	\checkmark	-	-	-	¢r 2022.	
Sign the informed consent form	V	-	-	-	- D	
Inclusion criteria	V	-	-	-	ownle	
Exclusion criteria	\checkmark	0 -	-	-	- ec	
Basic Information	\checkmark	G.	-	-	d fron	
Vital signs	\checkmark	V		\checkmark	√ Ètt	*
Index of laboratory inspection	*	*	×	*	://bm	
PSG	-	\checkmark		\checkmark	- jopei	
Pittsburgh sleep quality index(PSQI)	-	\checkmark	V	\checkmark	√ n.bmj	
Beck depression inventory(BDI)	-	\checkmark	V	V	√ ^{So}	
Beck anxiety inventory(BAI)		\checkmark		V	√ ON	
DBAS-16	-	\checkmark		V	-√ ^A pril	
Adverse Events	-	*	*	*	×*	*
Medication records	-	\checkmark		\checkmark	Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by gu	
Terminate test evaluation	-	*	*	*	ية الق الق الق	

Notes: **"X**"Record when necessary; PSG: Long-term scalp electroencephalogram recording; DBAS-16: Dysfunctional Bellefs and Attitudes about Sleep Scale 16 versio

will assign patients to either the treatment or control group. Researchers, which include statisticians, outcome assessors, and data analysts, will all be blinded to patients' group assignments. Although acupuncturists will be not blinded to group assignment, they will not be involved in outcome assessments or data analyses. In addition, all researchers will undergo training for specific procedures before the trial begins.

Participants and recruitment

Patients will be recruited using hospital-based advertisements in the Department of Acupuncture and Department of Neurology of the First Affiliated Hospital of Sun Yat-sen University from January 2022 to December 2025.

The inclusion criteria will be as follows: (1) meets diagnostic criteria for insomnia based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition^[26] and the International Classification of Sleep Disorders, Third Edition^[27], (2) aged 18–65 years, (3) experienced insomnia for more than 1 month but less than 2 years before the start of the trial, (4) voluntarily agrees to participate in the investigation and provides written informed consent before the clinical trial starts.

The exclusion criteria will be as follows: (1) serious cardiovascular, liver, kidney, or hematopoietic system disease, (2) insomnia was caused by a nervous system disease (e.g., stroke or Parkinson's disease), (3) insomnia was caused by a mental disorder, such as depression or anxiety, (4) history of sleep apnea, (5) pregnant or lactating women, (6) have received or currently receiving CBT-I.

Withdrawal criteria will be as follows: (1) patient withdrawal from the trial because of personal reasons, (2) patient has an adverse reaction related to acupuncture and refuses to continue treatment, (3) during the follow-up period, the patient cannot be contacted because of change of address and telephone number.

Intervention

The intervention will begin the day following randomization. All participants will receive 20 times treatments (five times per week for 4 weeks).

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

Observation group

Acupuncture treatment

Patients' skin will be disinfected with 75% alcohol, and patients will be asked to lie supine and wear eye masks for a better curative effect. Each participant will receive acupuncture treatment from the same acupuncturist who has more than 5 years of clinical experience in acupuncture therapy. The temperature of the treatment room will not be lower than 25°C.

Patients in the acupuncture group will receive electroacupuncture treatment on Sishenchong (EX-HN1), bilateral Neiguan (PC6), bilateral Taixi (KI3), bilateral Shenmen (HT7), and bilateral Sanyinjiao (SP6)^[28]. Tube-guided acupuncture needles will be inserted to a depth of 17-25 mm at each acupoint (acupuncture location and method for each acupoint are provided in Table 2 and Figure 2). A low-frequency electronic pulse therapy instrument (G6805-2A, Shanghai Huayi Medical Instrument Co., Shanghai, China) will be used with 10-Hz continuous waves, and the current will range from 1 to 5 mA which will be adjusted based on the tolerance of each patient.

CBT-I treatment

CBT-I will be given while acupuncture treatment is in progress. The intervention will consist of behavioral components (e.g. sleep restriction and stimulus control), cognitive components (e.g., cognitive restructuring and paradoxical intention), progressive muscle relaxation, and sleep hygiene^[29].

Control group

The procedure for the control group will be the same as that for the observation group with no CBT-I treatment. The major difference in interventions between the two groups being the tube needling method, in which no needle will be inserted through the tube for patients in the control group. To mimic the sensation of a real needle being inserted into the body, the acupuncturist will place the tube close to the skin at the acupoint and tap the top of the tube.

Quality control

The trial will be conducted under the supervision of the First Affiliated Hospital of Sun Yat-sun University. A qualified clinical trial expert will be invited to monitor the study to identify problems during the trial, examine collected data, and control bias.

Outcome measures

Primary outcome

Pittsburgh sleep quality index

The Pittsburgh sleep quality index (PSQI) is an internationally established tool that is used to evaluate sleep quality. The scale includes seven dimensions that consist of subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, sleeping medication, and daytime dysfunction. The score correlates adversely with sleep quality which a higher score means the sleep quality is worse, and each factor has a score of 0 to 3 to provide a total score of 21 points^[30, 31].

Secondary outcomes

The Beck depression inventory

The Beck depression inventory (BDI) is a valid self-assessment index to measure depression severity and consists of 13 items. Each item is scored from 0 to 3 (0 to 4 indicates no depression, 5 to 7 indicates mild depression, 8 to 15 indicates moderate depression), with a score of 16 points or more considered as severe depression^{[32-34].}

The Beck anxiety inventory

The Beck anxiety inventory (BAI) is used to assess the degree of anxiety and consists of 21 items scored from 1 to 4 (15 to 25 points indicates mild anxiety, 26 to 35 points indicates moderate anxiety, and 36 points is considered severe anxiety)^[35, 36].

The Dysfunctional Beliefs and Attitudes about Sleep Scale 16 version

The Dysfunctional Beliefs and Attitudes about Sleep Scale 16 version (DBAS-16) is used to evaluate maladaptive cognitions associated with sleep. There are 16 items in the index, which are divided into four factors comprising consequences of insomnia, worry about

	BMJ Open	acupoint 36/bmjopen-2022-063442 09 30 Dec Needling method
	Table 2 Acupuncture location and method for each	acupoint 9 3 Dec
Acupoint	Location	Needling method
Sishenchong (EX-HN1)	On the parietal region, 1 cun anterior ,posterior and lateral to Baihui, 4 acpoints totally.	The angle between the needle tip and the scalp is 30_{\circ} . Nove the needle tip backward along the anterioreposterior midline, and then meetle 0.5 cun.
Neiguan(PC6)	On the line joining Daling and Quze, between the tendons of palmaris longus and flexor carpi radialis, 2 cun above the transverse crease of the wrist.	Puncture perpendicularly 1-1.5 cun.
Taixi (KI3)	In the depression between the tip of the medial malleolus and the Achilles tendon.	Puncture perpendicalarly 0.5-1 cun.
Shenmen (HT7)	On the palmar ulnar end of the transverse crease of the wrist, and on the radial aspect of the tendon of the ulnar flexor m. of the wrist.	Puncture perpendicularly 0.5-1 cun.
Sanyinjiao (SP6)	Posterior to the mesial border of the tibia, and 3 cun above the tip of the medial malleolus	<u> </u>
	For peer review only - http://bmjopen.bmj.com/site/about/gui	18, 2024 by guest. Protected by copyright.

BMJ Open

sleep, sleep expectations, and medication. These factors are scored on a scale of 1-5(strongly disagree to strongly agree). The total score is positively correlated with the reasonableness of sleep beliefs and attitudes^[37, 38].

Sleep staging

The PARADISEP&D9600 (U.S.) Polysomnography Monitoring and Analysis System will be used to simultaneously monitor EEG, EOG, and EMG. A large clinical dataset of PSG recordings will be used to train a hybrid convolutional neural network (CNN) and recurrent neural network (RNN) to learn effective and generalizable features for sleep stage scoring^[39, 40]. Then clinical data will be used to indentify the deep learning algorithm. Sleep staging for both datasets will be performed by expert sleep technicians in nonoverlapping 30-s epochs according to standards by the American Academy of Sleep Medicine(AASM), as one of five stages: wake(W), non-rapid eye movement(REM) stage 1(N1), non-REM stage 2(N2), non-REM stage 3(N3), and rapid eye movement (REM)^[41].

Adverse events

During treatment and four week after treatment, a questionnaire will be administered to evaluate the various discomforts that may be caused by acupuncture: hangover, addiction, tolerance, fatigue after waking, insomnia rebound, daytime alertness, cognitive function, and behavior ability.

Patients and public involvement

Patients and the public are not involved in the design or conduct of the study or the outcome measures, and no attempt will be made to assess the burden of the intervention on the patients themselves. The results of this study will be disseminated to study participants via the website of our hospitals.

Statistical analysis

All analyses will be performed on the intention-to-treat population of participants who had at least one treatment. Missing data will be replaced according to the principle of the

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright

last observation carried forward. Data analyses will be performed using the SPSS version 25 (IBM Corp.) software. All available data will be analyzed descriptively. For continuous data, the normality test will be applied at the beginning of the analysis.
Results will be presented as means, standard deviations, and 95% confidence intervals (CIs) for continuous data that conform to the normal distribution and medians, quartiles, and ranges for rank data and continuous data that are not normally distributed. Discrete data will be presented as percentages.
We will first examine the descriptive data for sample characteristics at baseline, and independent samples t-tests will be used to compare groups for continuous variables,

independent samples t-tests will be used to compare groups for continuous variables, whereas chi-square analysis will be used to compare groups for dichotomous variables. Second, we will perform two series of repeated-measures and univariate analyses of covariance (ANCOVA) models to examine treatment effects. We will use repeated-measures ANCOVAs to analyze the primary and secondary outcome measures (i.e., PSQI, BDI, BAI, DBAS-16, and sleep staging scores) from pre-treatment to post-treatment. If a significant effect is observed, we will conduct posthoc paired samples t-tests to examine within-group changes in study outcomes. For all study outcomes, we will then perform univariate ANCOVAs to test for group differences in post-treatment values while controlling for relevant covariates. This process will be repeated to examine changes in study outcomes from pretreatment to postnatal follow-up.

When necessary, ITT analysis and sensitivity analysis will be used to assess the robustness of the conclusions of the entire clinical trial. To evaluate the consistency of the trial and explore the factors that affect efficacy or prognosis, subgroup analysis will be conducted to identify the population with better efficacy. Safety analysis will be used to assess the incidence of adverse events and related symptoms in patients with insomnia during treatment and follow-up.

Limitations

Currently, CBT-I is recommended as a first-line treatment for insomnia, but it is limited in clinical practice especially in developing countries such as China^[42-45]. As a complementary alternative therapy with a long history in China, acupuncture has been used as a clinical treatment for insomnia with fewer adverse effects and less permanent damage in previous studies^[13, 14, 16]. In this study, we will focus on whether electroacupuncture combined with CBT-I could influence sleep quality and sleep architecture, but whether acupuncture therapy alone could influence sleep habits and correct cognition, also sleep architecture worth futher research.

During the past decade, there have been various advances in automated sleep staging of PSGs data using the ability of deep learning methods to automatically extract features from data that are relevant to the classification, moreover, the performance of deep neural networks continues to improve as datasets become larger^[46-50]. To analyze the effects of electroacupuncture combined with CBT-I on sleep architecture, deep learning will be used to analyze PSGs in various clinical settings in this study. But due to lack of acceptability among patients, some of the participants received placebo treatment will drop, which may make analyses no meaningful due to the small number of participants in each arm. Notwithstanding, we will be able to optimize the randomized design and statistical analysis to avoid systematic errors and minimize the bias.

Ethics and dissemination

This trial has been approved by the institutional review boards and ethics committees of the First Affiliated Hospital of Sun Yat-sun University (2021763). The results will be disseminated through peer-reviewed journals. The results of this trial will be disseminated through peer-reviewed publications and conference abstracts or posters.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Acknowledgments

Not applicable.

Footnotes

Contributors: Wenya Pei and Te He designed the trial protocol and drafted the manuscript. Liming Lu, Jingwen Ruan, and Guihua Wen revised the manuscript. Pei Yang, Xiaozhou Lv, and Boyu Jiao will plan the data analysis. Liqian Cui, Yingshuo Yan, Fanqi Meng, Guanheng He, and Xin Zhou will participate in participant recruitment. All authors discussed, read, and revised the manuscript, and all approved the publication of this protocol.

Funding: The study was supported by the Key R&D Program of Guangdong Province (2020B1111120001).

Competing interests: None declared.

Patient consent for publication: Not applicable

Provenance and peer review: Not commissioned; externally peer-reviewed.

Ethics statements

Patient consent for publication

Not applicable.

Ethics approval and consent to participate: The study was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sun University (2021763). Participants will be included only after they provide written informed consent. The study was registered in the Chinese Clinical Trial Registry (No.ChiCTR2100052502, 30/10/2021).

References

1. Riemann D, Benz F, Dressle RJ, Espie CA, Johann AF, Blanken TF, Leerssen J, Wassing R, Henry AL, Kyle SD et al: Insomnia disorder: State of the science and challenges for the future. Journal of sleep research 2022, 31(4):e13604.

2. Chan WS, Levsen MP, McCrae CS: A meta-analysis of associations between obesity and insomnia diagnosis and symptoms. Sleep medicine reviews 2018, 40:170-182.

3. Wickwire EM: The Value of Digital Insomnia Therapeutics: What We Know and What We Need To Know. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2019, 15(1):11-13.

4. Kalmbach DA, Anderson JR, Drake CL: The impact of stress on sleep: Pathogenic sleep reactivity as a vulnerability to insomnia and circadian disorders. Journal of sleep research 2018, 27(6):e12710.

5. Shekleton JA, Flynn-Evans EE, Miller B, Epstein LJ, Kirsch D, Brogna LA, Burke LM, Bremer E, Murray JM, Gehrman P et al: Neurobehavioral performance impairment in insomnia: relationships with self-reported sleep and daytime functioning. Sleep 2014, 37(1):107-116.

Cross NE, Carrier J, Postuma RB, Gosselin N, Kakinami L, Thompson C, Chouchou F, Dang-Vu TT: Association between insomnia disorder and cognitive function in middle-aged and older adults: a cross-sectional analysis of the Canadian Longitudinal Study on Aging. Sleep 2019, 42(8).

7. Singareddy R, Vgontzas AN, Fernandez-Mendoza J, Liao D, Calhoun S, Shaffer ML, Bixler EO: Risk factors for incident chronic insomnia: a general population prospective study. Sleep medicine 2012, 13(4):346-353.

 Zhang Y, Ren R, Lei F, Zhou J, Zhang J, Wing YK, Sanford LD, Tang X: Worldwide and regional prevalence rates of co-occurrence of insomnia and insomnia symptoms with obstructive sleep apnea: A systematic review and meta-analysis. Sleep medicine reviews 2019, 45:1-17. 9. Kessler RC, Berglund PA, Coulouvrat C, Fitzgerald T, Hajak G, Roth T, Shahly V, Shillington AC, Stephenson JJ, Walsh JK: Insomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia Survey. Sleep 2012, 35(6):825-834.

Kalmbach DA, Cheng P, Arnedt JT, Cuamatzi-Castelan A, Atkinson RL,
 Fellman-Couture C, Roehrs T, Drake CL: Improving Daytime Functioning, Work
 Performance, and Quality of Life in Postmenopausal Women With Insomnia: Comparing
 Cognitive Behavioral Therapy for Insomnia, Sleep Restriction Therapy, and Sleep
 Hygiene Education. Journal of clinical sleep medicine : JCSM : official publication of the
 American Academy of Sleep Medicine 2019, 15(7):999-1010.

 Espie CA, Emsley R, Kyle SD, Gordon C, Drake CL, Siriwardena AN, Cape J, Ong JC, Sheaves B, Foster R et al: Effect of Digital Cognitive Behavioral Therapy for Insomnia on Health, Psychological Well-being, and Sleep-Related Quality of Life: A Randomized Clinical Trial. JAMA psychiatry 2019, 76(1):21-30.

 Thakral M, Von Korff M, McCurry SM, Morin CM, Vitiello MV: Changes in dysfunctional beliefs about sleep after cognitive behavioral therapy for insomnia: A systematic literature review and meta-analysis. Sleep medicine reviews 2020, 49:101230.
 Garland SN, Xie SX, DuHamel K, Bao T, Li Q, Barg FK, Song S, Kantoff P, Gehrman P, Mao JJ: Acupuncture Versus Cognitive Behavioral Therapy for Insomnia in Cancer Survivors: A Randomized Clinical Trial. Journal of the National Cancer Institute

2019, 111(12):1323-1331.

14. Liou KT, Root JC, Garland SN, Green J, Li Y, Li QS, Kantoff PW, Ahles TA, Mao JJ: Effects of acupuncture versus cognitive behavioral therapy on cognitive function in cancer survivors with insomnia: A secondary analysis of a randomized clinical trial. Cancer 2020, 126(13):3042-3052.

 Xing J, Wu X, Liu H, Wang J, Jiang S, Lozada A, Wang Y: Effects of Electroacupuncture Therapy and Cognitive Behavioral Therapy in Chronic Insomnia: A

Randomized Controlled Study. Evidence-based complementary and alternative medicine : eCAM 2020, 2020:5630130. 16. Cui L, Jingwen R, Minying Z, Guanheng H, Hao L: Effects of acupuncture combined with cognitive behavioral therapy on sleep quality, sleep belief and attitude in patients with chronic insomnia. Guangdong Medical Journal 2020, 41(10):1005-1009. 17. Ruan JW, Wang CH, Liao XX, Yan YS, Hu YH, Rao ZD, Wen M, Zeng XX, Lai XX: Electroacupuncture treatment of chronic insomniacs. Chin Med J (Engl) 2009, 122(23):2869-2873. 18. Yin X, Gou M, Xu J, Dong B, Yin P, Masquelin F, Wu J, Lao L, Xu S: Efficacy and safety of acupuncture treatment on primary insomnia: a randomized controlled trial. Sleep medicine 2017, 37:193-200. 19. Pei W, Peng R, Gu Y, Zhou X, Ruan J: Research trends of acupuncture therapy on insomnia in two decades (from 1999 to 2018):a bibliometric analysis. BMC complementary and alternative medicine 2019, 19(1):225. 20. Gorban AN, Makarov VA, Tyukin IY: The unreasonable effectiveness of small neural ensembles in high-dimensional brain. Physics of life reviews 2019, 29:55-88. 21. Bresch E, Großekathöfer U, Garcia-Molina G: Recurrent Deep Neural Networks for Real-Time Sleep Stage Classification From Single Channel EEG. Frontiers in computational neuroscience 2018, 12:85. 22. Hassan AR, Bhuiyan MIH: Automated identification of sleep states from EEG signals by means of ensemble empirical mode decomposition and random under sampling boosting. Computer methods and programs in biomedicine 2017, 140:201-210. 23. Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (Clinical research ed) 2010, 340:c332. 24. MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D: Revised STandards for Reporting Interventions in Clinical Trials of

Acupuncture (STRICTA): Extending the CONSORT statement. Journal of evidence-based medicine 2010, 3(3):140-155. 25. Wang C, Yang WJ, Yu XT, Fu C, Li JJ, Wang J, Xu WL, Zheng YX, Chen XY, Chen YF: Acupuncture for insomnia with short sleep duration: protocol for a randomised controlled trial. BMJ open 2020, 10(3):e033731. 26. Battle DE: Diagnostic and Statistical Manual of Mental Disorders (DSM). CoDAS 2013, 25(2):191-192. 27. Sateia MJ: International classification of sleep disorders-third edition: highlights and modifications. Chest 2014, 146(5):1387-1394. 28. Cui, L. Ruan, J, Zheng, M, He, G, Li H: Effects of acupuncture combined with cognitive behavioral therapy on sleep quality, sleep belief and attitude in patients with chronic insomnia. Guangdong Medical Journal 2020, 41(10):1005-1009. 29. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD: Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Annals of internal medicine 2016, 165(2):125-133. 30. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry research 1989, 28(2):193-213. 31. Mollayeva T, Thurairajah P, Burton K, Mollayeva S, Shapiro CM, Colantonio A: The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and meta-analysis. Sleep medicine reviews 2016, 25:52-73. 32. Robinson BE, Kelley L: Concurrent validity of the Beck Depression Inventory as a measure of depression. Psychological reports 1996, 79(3 Pt 1):929-930. 33. Piotrowski C: Use of the Beck Depression Inventory in clinical practice. Psychological reports 1996, 79(3 Pt 1):873-874.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

34. Carney CE, Ulmer C, Edinger JD, Krystal AD, Knauss F: Assessing depression symptoms in those with insomnia: an examination of the beck depression inventory second edition (BDI-II). Journal of psychiatric research 2009, 43(5):576-582.

35. Beck AT, Epstein N, Brown G, Steer RA: An inventory for measuring clinical anxiety: psychometric properties. Journal of consulting and clinical psychology 1988, 56(6):893-897.

36. Nyer M, Farabaugh A, Fehling K, Soskin D, Holt D, Papakostas GI, Pedrelli P, Fava M, Pisoni A, Vitolo O et al: Relationship between sleep disturbance and depression, anxiety, and functioning in college students. Depression and anxiety 2013,

30(9):873-880.

37. Morin CM, Vallières A, Ivers H: Dysfunctional beliefs and attitudes about sleep (DBAS): validation of a brief version (DBAS-16). Sleep 2007, 30(11):1547-1554.

38. Chung KF, Ho FY, Yeung WF: Psychometric Comparison of the Full and Abbreviated Versions of the Dysfunctional Beliefs and Attitudes about Sleep Scale. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2016, 12(6):821-828.

39. Ramaswamy SM, Weerink MAS, Struys M, Nagaraj SB: Dexmedetomidine-induced deep sedation mimics non-rapid eye movement stage 3 sleep: large-scale validation using machine learning. Sleep 2021, 44(2).

40. Abou Jaoude M, Sun H, Pellerin KR, Pavlova M, Sarkis RA, Cash SS, Westover MB, Lam AD: Expert-level automated sleep staging of long-term scalp electroencephalography recordings using deep learning. Sleep 2020, 43(11).

41. Malhotra RK, Kirsch DB, Kristo DA, Olson EJ, Aurora RN, Carden KA, Chervin RD, Martin JL, Ramar K, Rosen CL et al: Polysomnography for Obstructive Sleep Apnea Should Include Arousal-Based Scoring: An American Academy of Sleep Medicine Position Statement. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2018, 14(7):1245-1247.

42. Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, Espie
CA, Garcia-Borreguero D, Gjerstad M, Gonçalves M et al: European guideline for the
diagnosis and treatment of insomnia. Journal of sleep research 2017, 26(6):675-700.
43. Kathol RG, Arnedt JT: Cognitive Behavioral Therapy for Chronic Insomnia:

Confronting the Challenges to Implementation. Annals of internal medicine 2016, 165(2):149-150.

44. Ree M, Junge M, Cunnington D: Australasian Sleep Association position statement regarding the use of psychological/behavioral treatments in the management of insomnia in adults. Sleep medicine 2017, 36 Suppl 1:S43-s47.

45. Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ, Lichstein KL, Sateia MJ, Troxel WM, Zhou ES, Kazmi U et al: Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2021, 17(2):255-262.

46. Zhang L, Fabbri D, Upender R, Kent D: Automated sleep stage scoring of the Sleep Heart Health Study using deep neural networks. Sleep 2019, 42(11).

47. Feige B, Baumgartner B, Meyer D, Riemann D: The Relationship Between PSG and Morning/Evening Emotional Parameters in Patients With Insomnia Disorder and Good Sleepers. Frontiers in psychology 2018, 9:2712.

48. Lajnef T, Chaibi S, Ruby P, Aguera PE, Eichenlaub JB, Samet M, Kachouri A, Jerbi K: Learning machines and sleeping brains: Automatic sleep stage classification using decision-tree multi-class support vector machines. Journal of neuroscience methods 2015, 250:94-105.

49. Qu W, Wang Z, Hong H, Chi Z, Feng DD, Grunstein R, Gordon C: A Residual Based Attention Model for EEG Based Sleep Staging. IEEE journal of biomedical and health informatics 2020, 24(10):2833-2843.


50. Wang Y, Loparo KA, Kelly MR, Kaplan RF: Evaluation of an automated single-channel sleep staging algorithm. Nature and science of sleep 2015, 7:101-111.


ow Diagram ts Fig 1. CONSORT 2010 Flow Diagram

Fig 2. Location of acupoints

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright.

BMJ Open: first published as 10.1136/bmjopen-2022-063442 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright.





33 34

		BMJ Open g	
		BMJ Open SPRICE Standard Protocol Items: Recommendations for Interventional Trials	
SPIRIT 2013 Check Section/item	list: Reco Item No	Description Desc	Addressed on page number
Administrative info	ormatior	n Downlog	
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicate, trial acronym	<u>1</u>
Trial registration	2a		<u>1</u>
	2b	Trial identifier and registry name. If not yet registered, name of intended registry All items from the World Health Organization Trial Registration Data Set	<u>1</u>
Protocol version	3	Date and version identifier	<u>1</u>
Funding	4	Sources and types of financial, material, and other support	<u>12</u>
Roles and	5a	Names, affiliations, and roles of protocol contributors	<u>1,12</u>
responsibilities	5b	Name and contact information for the trial sponsor	<u>12</u>
	5c	Role of study sponsor and funders, if any, in study design; collection, management, a all all sis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	<u>12</u>
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups over seeing the trial, if applicable (see Item 21a for data monitoring committee)	<u>NA</u>

Page	25	of	29
------	----	----	----

Page	25 of 29		BMJ Open	
1 2	Introduction		2022-06	
2 3 4 5	Background and rationale	6a	مع Description of research question and justification for undertaking the trial, including semmary of relevant studies (published and unpublished) examining benefits and harms for each	<u>3-4</u>
6 7		6b	Explanation for choice of comparators $\begin{tabular}{c} & & & & & \\ & & & & & & \\ & & & & & & $	<u>5</u>
8 9	Objectives	7	Specific objectives or hypotheses	<u>4</u>
10 11 12 13	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factoria single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	<u>4</u>
14 15	Methods: Participa	nts, int	erventions, and outcomes	
16 17 18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	<u>4-5</u>
19 20 21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	<u>6</u>
22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	<u>6-7</u>
		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	<u>6</u>
		11c	Strategies to improve adherence to intervention protocols, and any procedures for menitoring adherence (eg, drug tablet return, laboratory tests)	<u>6</u>
		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	<u>6</u>
	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	<u>7-9</u>
	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	4,Table 1,Figure 1
43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 26 of 29

			BMJ Open			
1 2 3 4 5 6 7	Sample size	14	Estimated number of participants needed to achieve study objectives and how it wasketermined, including clinical and statistical assumptions supporting any sample size calculationsໍ່ລູ			
	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size $\frac{43}{9}$	<u>8-9</u>		
	Methods: Assignment of interventions (for controlled trials)					
8 9	Allocation:			<u>5</u>		
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is up available to those who enrol participants or assign interventions	<u>5</u>		
	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequent ally numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	<u>5</u>		
	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	<u>5</u>		
	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	<u>5</u>		
27 28 29		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	<u>5</u>		
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45	Methods: Data coll	ection,	management, and analysis			
	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be four d, if not in the protocol	<u>9</u>		
		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	<u>9</u>		

Page	27	of	29
------	----	----	----

Page 27 of 29			BMJ Open	
1 2 3 4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>9-10</u>
5 6 7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>9-10</u>
8 9		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>9-19</u>
10 11 12 13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>9-10</u>
14 15	Methods: Monitorir	ng	n load	
16 17 18 19 20	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>9-10</u>
21 22 23 24		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>9-10</u>
25 26 27	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously eported adverse events and other unintended effects of trial interventions or trial conduct	<u>9-10</u>
28 29 30 31	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>9-10</u>
32 33	Ethics and dissemi	ination	2024 by g	
34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) ap ਸ਼੍ਰਾ	<u>5</u>
37 38 39 40 41 42 43	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility cetteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>NA</u>
44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

			BMJ Open	mjopen			Р
1 2	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authori surrogates, and how (see Item 32)	-20 % -0632		<u>6</u>	
3 4 5 6		26b	Additional consent provisions for collection and use of participant data and biological ancillary studies, if applicable	¹⁴ Specimens in S		<u>6</u>	
7 8 9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, maintained in order to protect confidentiality before, during, and after the trial	ପ୍ରକାର Shared, and		<u>6</u>	
10 11 12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial study site	and each		<u>12</u>	
13 14 15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contrac agreements that limit such access for investigators	ow Bijal Doadeo		<u>6</u>	
16 17 18 19	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who from trial participation	a suffer harm		<u>6</u>	
20 21 22 23	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healt professionals, the public, and other relevant groups (eg, via publication, reporting in databases, or other data sharing arrangements), including any publication restriction	sults		<u>6</u>	
24 25 26 27 28 29		31b	Authorship eligibility guidelines and any intended use of professional writers	mj.co		<u>6</u>	
		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, code	agnd statistical April 18		<u>6</u>	
30 31	Appendices			3, 202			
32 33	Informed consent	32	Model consent form and other related documentation given to participants and author	uesed	See	The	Ethics
34 35 36	materials		surrogates	juest. Prof	<u>Approv</u>	Approval Docume	<u>ument</u>
37 38 39	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for gemolecular analysis in the current trial and for future use in ancillary studies, if application	etic or		<u>NA</u>	
40 41 42 43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	copyright.			

 mjopen-

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons an http://brinjopen.brinj.com/ on April 18. "Attribution-NonCommercial-NoDerivs 3.0 Unported" license. 42 on 30 December 2022. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright